Cv-first.pdf

CURRICULUM VITAE
Martin Roy First
Division of Nephrology & Hypertension MARITAL STATUS: Married - 2 children CITIZENSHIP: University of Witwatersrand, M.B., B.Ch., 1966 House Surgeon, Johannesburg General Hospital Johannesburg, South Africa, January – June, 1967 House Physician, Johannesburg General Hospital Johannesburg, South Africa, July - December, 1967 Medical Officer, South African Defense Force Pretoria, South Africa, January - December, 1968 Registrar, Johannesburg General Hospital and Department of Medicine, University of Witwatersrand, Johannesburg, South Africa, January 1969 - December 1971 Renal Research Fellow, Michael Reese Hospital Chicago, Illinois, May 1972 - April 1973 Renal Fellow, University of Cincinnati Medical Center Cincinnati, Ohio, May 1973 - February 1974 Assistant Professor of Medicine, Division of Nephrology Department of Internal Medicine, University of Cincinnati Medical Center, March 1974 - August 1978 Associate Professor of Medicine, Division of Nephrology Department of Internal Medicine, University of Cincinnati Medical Center, September 1978 - August 1985 Professor of Medicine, Division of Nephrology, Department of Internal Medicine, University of Cincinnati Medical Center, September 1985 - Present Cincinnati Veterans Administration Hospital, 1977 - Director, Section of Transplantation, University of Cincinnati Medical Center, Division of Nephrology, 1987 - Present American Federation for Clinical Research American Society of Transplant Physicians Pan American Society of Dialysis and Transplantation European Dialysis and Transplant Association South African Medical and Dental Council, January 1967 General Medical Council of the United Kingdom, January 1972 Illinois License (Flex Examination) December 1973 Education Council for Foreign Medical Graduates Fellow of College Physicians of South Africa American Board of Internal Medicine, June 1976 American Boards of Nephrology, October 1976 University of Cincinnati Medical Center
Internal Medicine Search Committee for Chairman of Department of Internal Medicine 1975-1977 Internal Medicine Residents Selection Committee 1976-1990 Internal Medicine Audit Committee 1977-1978 Faculty Representataive of Department of Medicine on Research and Education Fund Board of Trustees 1978-1980 University of Cincinnati Medical Center Committee on University of Cincinnati Medical Center Committee on University of Cincinnati Medical Center Ad Hoc Nominating Committee for the Appointments and Promotions Committee, 1982 University of Cincinnati Medical Center, Department of Internal Medicine Promotions and Tenure Committee, 1982-1991 Executive Committee of the Medical Center Fund of Cincinnati, 1987-1991 University of Cincinnati Medical Center, Department of Internal Medicine Chairman, Promotions and Tenure Committee, 1989-1991 University of Cincinnati Medical Center Associates (UCMA) Faculty Achievement Award winner for significant contributions to the Executive Committee of the Medical Staff of the University Hospital, 2000 -present Regional
Health Planning Association of the Central Ohio River Valley (CORVA) Kidney Disease Coordinating Committee 1974-1976 Ohio Valley Organ Procurement Program (OVOPP) 1975-1978 - Research Advisory Committee, 1977-1979 - Vice-Chairman of Medical Advisory Board, 1981-1983 - Chairman, Direct Patient Services Committee, 1981-1983 - Chairman, Medical Advisory Board, 1983-1987 - Cincinnati General Hospital Representative to the - Director, Bylaws and Procedures Committee, 1980-1981 - Organ Retrieval and Transplant Committee, 1980 - Kentucky Colonel - (Appointed by Governor Brown 1982 for outstanding contribution t o the community) Executive Committee, Ohio Valley Life Center, 1996- National
Representative of Kidney Foundation of Greater Cincinnati to the National Kidney Foundation Medical Advisory Board 1978 Alternate Representative, University of Cincinnati Medical Center, Southeastern Organ Procurement Foundation (SEOPF) Membership Committee of American Society of Transplant Board of Directors, Region 2, United Network For Organ Sharing Chairman, Membership Committee of American Society of Councillor, American Society of Transplant Physicians, 1986 -1992 Member, for Training and Certification of Transplant Physicians, American Society of Transplant Physicians, 1986 -1992 President, American Society of Transplant Physicians, 1990-1991 Advisory Committee, American Society of Transplant Physicians, 1991 -1997 Awards Committee, American Society of Transplant Physicians, 1991-1993 United Network for Organ Sharing (UNOS), 1993-1995 National Kidney and Urologic Diseases Advisory Board, Task Force on Chairman, Ortho Biotech Transplant Institute, 1995 -1997 Scientific Studies Committee, United Network for Organ Sharing Program and Publications Committee, American Society of Transplant Physicians Co-chairman , Organ Donation Committee, American Society of Transplant Ad Hoc Committee on Steroid Withdrawal in Solid Organ Transplantation, American Society of Transplant Physicians, 1998-1999 Patient Care and Education Committee, American Society of Transplantation, Ad Hoc Task Force on AST Election Procedure, American Society of Transplantation, 2001-2002 Clinical Trials Committee, The Council of American Kidney Societies, Scientific Advisory Board, National Kidney Foundation, 1998-2000 Chairman, Organ Donation Committee, American Society of Transplant Data and Safety Monitoring Board, Cooperative Clinical Trials in Transplantation, National Institutes of Health, 1998 - Councillor, International Transplantation Society, 1998- Food and Drug Administration, Center for Drug Evaluation and Research, Patient Education Committee, American Society of Transplantation, 2000- - Literature Scan: Transplantation, 1991 - - Associate Editor, American Journal of Kidney Disease, 1992 - - Section Editor, Transplantation, The Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), 2nd edition, Mobsy-Year Book, Inc., - Editorial Board, Transplantation Proceedings, 1996 - - Editorial Board, Transplantation, 1996 - - Journal of the American Society of Nephrology, 1996 - - Assistant Editor, American Society of Transplant Physicians Newsletter, 1996 - - Graft, 1998 – - Associate Editor, Graft. 2000- - American Journal of Tansplantation, 2000- - Journal of the American Medical Association - Journal of American Society of Nephrology National Institute of Allergy and Infectious Diseases (NIAID) special review committee on Transplantation Immunology, 1992 Chairperson, Clinical Transplantation Abstract Selection Committee Department of Health and Human Services, Food and Drug Administration, Office of Orphan Products Development Grant Program, Ad hoc reviewer, BIBLIOGRAPHY
MARTIN ROY FIRST, M.D.
______________________________________________________________________________ First MR. Skull fractures in suid fossils from Makapansgat. Leech 34: 143. 1964 (Publication of Witwatersrand Medical School). First MR, Jacobson R, Goldin AR, Seftel HC. Acute methyl alcohol poisoning. S Afr Med J 44:503-505, 1970 Kew MC, First MR. A trial of Ro 4-2137 in the treatment of hypertension. Curr Ther Res 14:343-348, 1972 First MR. Familial systemic lupus erythematosus. S Afr Med J 47:147, 1973 First MR. Sodium handling by the kidney in health and disease. S Afr Med J 47:839-843, 1973 Ooi BS, Orlina AR, Masaitis L, First MR, Pollak VE, Ooi YM. Lymphocytotoxins in aging. Transplantation 18:190-192, 1974 Ooi BS, First MR, Pesce AJ, Pollak VE, Bernstein IL, Jao W. IgE levels in interstitial nephritis. Lancet 1:1254-1256, 1974 Pollak VE, First MR, Pesce AJ. Value of the sieving coefficient in the interpretation of renal protein clearances. Nephron 13:82-89, 1974 Clyne DH, Brendstrup L, First MR, Pesce AJ, Finkel PN, Pollak VE, Pirani CL. Renal effects of intraperitoneal Kappa chain injection: induction of crystals in renal tubular cells. Lab Invest 31:131-142, 1974 Ooi BS, Jao W, First MR, Mancilla R, Pollak VE. Acute interstitial nephritis. Am J Med 59:614-629, 1975 Alexander JW, Smith EJ, McAdams AJ, Fidler JP, First MR, Muthiah V, Alexander NS, Korelitz J. Comparison of goat ATLG and ASLG in human renal transplants. J Surg Res 19:287-295, 1975 Munda R, Alexander JW, Fidler JP, First MR. Use of dacron vascular graft in arterial stenosis following renal allograft transplantation. Am Surg 42:604-607, 1976 First MR. Effects of chronic lead exposure on the kidney. Seminar on lead exposure and toxic effects, National Institute of Occupation Safety and Health, 8-11, Cincinnati, Ohio, 1976 Linnemann CC, First MR, Alvira MM, Alexander JW, Schiff GM. Herpes hominis type 2 meningoencephalitis following renal transplantation. Am J Med 61:703-708, 1976 First MR, Sloan DE, Pesce AJ, Pollak VE. Albumin excretion by the kidney: the effects of volume expansion. J Lab Clin Med 89:25-29, 1977 Munda R, First MR, Alexander JW, Fidler JP, Gartside P. Pulmonary infections following renal transplantation. Proc Clin Dial Transpl Forum 6:1-7, 1976 Sethi K, First MR, Pesce AJ, Fidler JP, Pollak VE. Proteinuria following renal transplantation. Nephron 18:49-59, 1977 Ooi YM, Ooi BS, Vallota EH, First MR, Pollak VE. Circulating immune complexes after renal transplantation: Correlation of increased 125I-Clq binding activity with acute rejection characterized by fibrin deposition in the kidney. J Clin Invest 60:611-619, 1977 Munda R, Alexander JW, Miller S, First MR, Fidler JP. Renal allograft artery stenosis. Am J Surg 134:400-403, 1977 First MR, Linnemann CC, Munda R, McConnell CM, Ramundo N, Alexander JW, Nathan P. Transmitted streptococcal infection and hyperacute rejection: Possible cross-reaction of streptococcal antigens and antibodies with mammalian tissues. Transplantation 24:400-404, 1977 First MR, Patel VP, Pesce AJ, Bramlage RJ, Pollak VE. Albumin excretion by the kidney: The effects of osmotic diuresis. Nephron 20:171-175, 1978 Munda R, Alexander JW, Fidler JP, First MR, Gartside P. Pulmonary infections in renal transplant recipients. Ann Surg 197:126-133, 1978 First MR, Ooi BS, Jao W, Pollak VE. Pre-eclampsia and the nephrotic syndrome. Kidney Int 13:166-177, 1978 Linnemann CC, Dunn CR, First MR, Alvira M, Schiff GM. Late onset of fatal cytomegalovirus infection after transplantation. Arch Int Med 138:1247-1250, 1978 Fidler JP, Dajani F, First MR, Munda R, Alexander JW. The value of urine cytology in renal transplantation. Transplantation 26:133-134, 1978 Stinnett JD, Alexander JW, Ogle CK, McClellan MA, Brady D, First MR. Immune function of kidney transplant patients in relation to infection. Transplant Proc 10:639-645, 1978 First MR, Bramlage RJ, Pesce AJ, Pollak VE. Albumin excretion by the kidney: The effects of furosemide diuresis. Proc Soc Exp Biol Med 158:550-553, 1978 Munda R, Alexander JW, First MR, Fidler JP. Hypothermic pulsatile perfusion and transplantation of pediatric cadaveric kidneys into adults. Am Surg 44:451-454, 1978 Linnemann CC, Kaufman CA, First MR, Schiff GM, Phair JP. Immune response to cytomegalovirus infection after renal transplantation. Infection and Immunity 22:176-180, 1978 Nathan P, Plessinger RT, First MR. The correlation of kidney transplant survival with lymphocyte mediated cytotoxicity on B cell targets. Proc Clin Dial Transpl Forum 8:62o-67, 1979 Linnemann CC, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 241:2619-2621, 1979 Hong CD, Kapoor BS, First MR, Pollak VE, Alexander JW. Fractional excretion of sodium after renal transplantation. Kidney Int 16:167-178, 1979 Majeski JA, Alexander JW, First MR, Munda R, Fidler JP. Transplantation of a horseshoe kidney. JAMA 242:1066, 1979 Spreng WM, Nathan PE, First MR. BW-4/BW-6 matching and renal allograft survival in hemozygous recipients. Proc Clin Dial Transpl Forum 9:93-94, 1979 Munda R, Alexander JW, First MR, Knowles HC, Weiss MA. Synchronous transplantation of a kidney and duct obliterated segmental pancreas. Report of a case. Transplant Proc 12:98-102, 1980 First MR, Munda R, Kant KS, Fidler JP, Alexander JW. Steroid withdrawal following HLA -identical related donor transplantation. Transplant Proc 13:319-322, 1981 Munda R, Alexander JW, First MR, Laver MC, Majeski JA. Autotransplanta- tion and ex-vivo surgery for renovascular disease. Arch Surg 116:772-777, 1981 First MR, Glueck CJ. Plasma lipids and coronary heart disease in renal failure. Int J Artif Organs 4: 120-122, 1981 Barcelli U, Crissman J, First MR, Pollak VE. Rapidly progressing arterio-occlusive syndrome (Kohlmeier-Degos' disease?) in a patient on chronic hemodialysis. Arch Int Med 141:1331-1335, 1981 Linnemann CC, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Int Med 141:1637-1640, 1981 Majeski JA, Alexander JW, First MR, Munda R, Fidler JP. Microbial contamination of transplanted cadaver kidneys. Ann Surg 117:221-224, 1982 Roy MT, First MR, Myre SA, Cacini W. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects. Therap Drug Monitoring 4:77-79, 1982 Dosekun AK, First MR, Chandran PKG, Kant KS, Glas-Greenwalt P, Weiss MA, Alexander JW, Pollak VE. Successful treatment by defibrination with ancrod in a patient with hyperacute renal allograft failure and a deficiency of plasma prostacyclin stimulating factor. Clin Nephrol 18:101-105, 1982 Kuller J, First MR, D'Achiardi R, Munda R. Pneumocystis carinii pneumonia in renal transplant recipients. Am J Nephrol 2:312-315, 1982 Chandran PKG, First MR, Weiss MA, Hess EV, Alexander JW, Pazmino P. Wegener's granulomatosis: Prolonged patient survival after pneumonectomy and renal transplantation. Am J Nephrol 2:325-329, 1982 Chandran PKG, First MR, Wegener's granulometosis, clinical - pathological correlations and long-term course (letter). Am J Kidney Dis. 1:255, 1982. Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, Kittur D. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 249:219-222, 1983 Levine MG, Miodovnik M, Siddiqu TA, First MR, Knowles HC. A successful pregnancy in a juvenile diabetic with a renal transplant complicated by preeclampsia. Transplantation 35:498-499, 1983 First MR, Munda R. Secondary vascular access for hemodialysis. Int J Artif Organs 6:107-108, 1983 First MR, Glueck CJ. Black-white differences in high density lipoproteins, apolipoproteins, and triglycerides: Relationship to coronary heart disease in non-uremic populations and in uremic subjects receiving hemodialysis. Int J Artif Organs 6:233-234, 1983 Munda R, First MR, Suttman MP, Alexander JW. Simultaneous kidney and pancreas procurement. Transplant Proc 16:248-250, 1984 Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, Morris MJ, Suttman MP. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 37:467-470, 1984 Munda R, First MR, Webb C, Alexander JW. Clinical experience with segmental pancreatic allografts. Transplant Proc 16:692-694, 1984 First MR, Ettenger M, Robson M, Pollak VE, Ooi BS, Goldberg M. Acute deterioration in renal function in patients with pre-existing renal dis ease. Arch Int Med 144:2233-2238, 1984 First MR, Mendoza N, Maryniak RK, Weiss MA. Membranous glomerulopathy following kidney transplantation: Association with renal vein thrombosis in 2 of 9 cases. Transplantation 38:603-607, 1984 First MR, Vaidya PN, Maryniak RK, Weiss MA, Munda R, Fidler JP, Penn I, Alexander JW. Proteinuria following transplantation: Correlation with histopathology and outcome. Transplantation 38:607-614, 1984 Garcia-Garcia G, Deddens JA, D'Achiardi-Rey R, First MR, Samuels SJ, Kant KS, Pollak VE. Results of treatment in patients with end-stage renal disease: A multivariate analysis of risk factors and survival in 341 successive patients. Am J Kidney Dis 5:10-18, 1985 Meakin CJ, Hopson CN, First MR. Avascular (Aseptic) necrosis of bone following renal transplantation. Int J Artif Organs 8:19-20, 1985 First MR, Linnemann CC, Munda R, Alexander JW. Beneficial effects of pneumococcal polysaccharide vaccine in splenectomized renal transplant recipients. Transplant Proc 17:147-150, 1985 Munda R, First MR, Joffe SN, Alexander JW. Experience with pancreatic allografts in renal transplant recipients. Transplant Proc 17:353-357, 1985 Maryniak RK, Weiss MA, First MR. Transplant glomerulopathy--Evolution of morphologically distinct changes. Kidney Int 27:799-806, 1985 Hayes DK, Majeski JA, Alexander JW, Rajagopalan PR, Fitts G, First MR, Munda R, Fidler JP. Renal transplantation in Alport's syndrome. Am Surg 51:414-417, 1985 Goldstein G, Schindler J, Tsai H, Cosimi AB, Russell PS, Cho SI, Burdick JF, Williams GM, Stuart FP, Shields CF, Alexander JW, First MR, Gailiunas P, Helderman JH, Wathen RL, Lordon RE, Normal D, Barry J, Sampson D, Levin BS, Monaco A. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985 Balakrishnan K, Whitacre L, First MR, Munda R, McEnery PT, Alexander JW. Donor-specific transfusions: Sensitization patterns. Transplant Proc 17:2354-2356, 1985 Schroeder TJ, Wadhwa NK, Pesce AJ, First MR. An acute overdose of cyclosporine. Transplantation 41:406-409, 1986 First MR, Alexander JW, Wadhwa N, Penn I, Munda R, Fidler JP, Weiskittel P. The use of low doses of cyclosporine, azathioprine, and prednisone in renal transplantation. Transplant Proc 18:132-135, 1986 Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 18:210-213, 1986 Linnemann CJ, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Int Med 146:1554-1556, 1986 Munda R, Tom WT, First MR, Gartside P, Alexander JW. Pancreatic allograft exocrine urinary tract diversion: Pathophysiology. Transplantation 43:95-99, 1987 Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 19:1730-1733, 1987 Tom WT, Munda R, First MR, Alexander JW. Physiologic consequences of pancreatic allograft exocrine drainage into the urinary tract. Transplant Proc 19:2339-2342, 1987 Munda R, Weiss MA, First MR, Alexander JW. Sychronous pancreatic and renal allografts with urinary tract drainage of the pancreas. Transplant Proc 19:2343-2344, 1987 Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 43:211-213, 1987 Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, Munda R, First MR. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Therap Drug Monitoring 9:123-125, 1987 Myre SA, McCann J, First MR, Cluxton RJ. Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Therap Drug Monitoring 9:161-165, 1987 Schroeder TJ, Melvin DB, Clardy CW, Wadhwa NK, Myre SA, Reising JM, Wolf RK, Collins JA, Pesce AJ, First MR. The use of cyclosporine and ketoconazole without nephrotoxicity in two cardiac transplant recipients. J Heart Transplant 6:84-89, 1987 Tom WT, Munda R, First MR, Alexander JW. Autodigestion of the glans penis and urethra by activated transplant pancreatic exocrine enzymes. Surgery 102:99-101, 1987 Munda R, First MR, Weiss MA, Alexander JW. Pancreas transplantation at the University of Cincinnati. Transplant Proc 19:17-23, 1987 Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CW, First MR. Cyclosporine drug interactions. Therap Drug Monitoring 9:399-406, 1987 Waymack JP, Penn I, First MR, Alexander JW. Portal vein gas and sepsis after administration of OKT3 (letter). Lancet 1:984, 1987. Weir MR, Henry M, Blackmore M, Smith J, First MR, Irwin B, Shen S, Genemans G, Alexander JW, Corry RJ, Nghiem DD, Ferguson R, Kittur D, Shield CF III, Sommer B, Williams FM. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor specific transfusion and living related donor transplantation: A multi-center evaluation. Transplantation 45:111-116, 1988 Schroeder TJ, Pesce AJ, Hassan FM, Wermeling JR, Warner A, Schlueter KT, First MR. Comparison of Abbott TDX fluorescence polarization immunoassay (FPIA), Sandoz radioimmunoassay (RU), and high performance liquid chromatography (HPLC) methods for assay of serum cyclosporine. Transplant Proc 20(Suppl 2):345-347, 1988 Munda R, Schroeder TJ, Pedersen S, Clardy CW, Wadhwa NK, Myre SA, Pesce AJ, First MR. Cyclosporine pharmacokinetics in pancreas transplant recipients. Transplant Proc 20(Suppl 2):487-490, 1988 Myre SA, Schroeder TJ, Melvin DB, Clardy CW, Pesce AJ, Wadhwa NK, Collins JA, Wolf RK, Brown LL, Stephens GW, First MR. Use of cyclosporine by constant-rate intravenous infusion immediately following heart transplantation. Transplant Proc 20(Suppl 3):316-322, 1988 Shah B, First MR, Mendoza NC, Clyne DH, Alexander JW, Weiss MA. Alport's syndrome: Risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 50:34-38, 1988 First MR, Schroeder TJ. Monoclonal antibodies in organ transplantation. Clin Transplant 2:162, 1988 First MR, Schroeder TJ, Melvin DB, Munda R, Fidler JP, Balistreri WF, Hurtubise PE, Alexander JW, Penn I, Ryckman FD. OKT3 therapy in kidney, liver, heart and pancreas transplantation. Clin Transplant 2:185-189, 1988 Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balistreri WF, Harris RE, Melvin DB. The clinical variability of cyclosporine pharmacokinetics in adult and pediatric renal, cardiac, hepatic and bone marrow transplants. Clin Chem 34:2012-2015, 1988 Shah B, First MR, Munda R, Penn I, Fidler JP, Alexander JW. Current experience with renal transplantation in older patients. Am J Kidney Dis 12:516-523, 1988 First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP, Ryckman FC, Brunson ME. Successful retreatment of allograft rejection with OKT3. Transplantation 47:88-91, 1989 Schroeder TJ, Brunson ME, Pesce AJ, Hindenlang LL, Mauser PA, Ruckrigl DL, Weibel ML, Wadih G, First MR. A comparison of the clinical utility of the RIA, HPLC, and TDX cyclosporine assays in outpatient renal transplant recipients. Transplantation 47:262-266, 1989 Schroeder TJ, Myre SA, Melvin DB, Stephens GW, Collins JA, Van Der Bel Kahn, J, Wolf RK, Brown LL, Pesce AJ, First MR. The efficacy and safety of constant rate intravenous cyclosporine infusion immediately following cardiac transplantation. J Heart Transplant 8:5-10, 1989 First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, Stephens GW, Penn I, Alexander JW. Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation. Transplant Proc 21:1567-1570, 1989 Hariharan S, First MR, Munda R, Penn I, Schroeder TJ, Fidler J, Weiskittel P, Alexander JW. Prednisone withdrawal in HLA -identical living related donor transplant recipients. Transplant Proc 21:1617-1619, 1989 First MR, Schroeder T, Penn I, Munda R, Balistreri W, Alexander JW, Melvin D, Ryckman F, Brunson M. Immune monitoring during retreatment with OKT3. Transplant Proc 21:1753-1754, 1989 Munda R, Hutchins M, First MR, Carey M, Schroeder T, Alexander JW. Infection in OKT3 treated patients receiving additional antirejection therapy. Transplant Proc 21:1763-1765, 1989 Balakrishnan K, Munda R, First MR, Alexander JW. Outcome of kidney transplants across B cell positive crossmatches. Transplant Proc 21:1836, 1989 Schroeder T, Gremse D, Mansour M, Theurling A, Brunson M, Ryckman F, Suchy F, Penn I, Alexander W, Pesce AJ, First MR, Balistreri WF. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients. Transplant Proc 21:2299-2301, 1989 Myre S, Melvin D, Pesce A, Schroeder T, Collins J, Stephens G, Kahn A, First MR. Comparison of the safety and efficacy of oral vs constant-rate intravenous infusion cyclosporine immediately following orthotopic heart transplantation. Transplant Proc 21:2484-2486, 1989 100. Munda R, First MR, Kranias G, Alexander JW. Effects of pancreatic transplantation on diabetic complications. Schroeder TJ, Pesce AJ, Hindelang LL, Mauser PA, Ruckrigl DL, Weibel ML, Wadih G, First MR. An evaluation of the cyclosporine and metabolites whole blood TDX assay. Therap. Drug Monit 11:480-482, 1989 Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Monsour ME, Melvin DB. Immunological monitoring with orthoclone OKT3 therapy. J Heart Transplant 8:371-380, 1989 Schroeder TS, First MR, Mansour ME, Alexander JW, Penn I. Prophylactic use of OKT3 in immunological high risk renal transplant recipients. Am J Kidney Dis 14 (Suppl 2):14-18, 1989 First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 2:1198-1201, 1989 First MR, Schroeder TJ, Carey MA, Chavinson DS. Effect of race on transplant outcome and response to OKT3 monoclonal antibody therapy. Transplant Proc 21:3849-3952, 1989 Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Ballistreri WF, Alexander JW. Antimurine antibody formation following OKT3 therapy. Transplantation 49:48-51, 1990 Schroeder TJ, Munda R, Pederson SH, Hurtubise SH, Alexander JW, First MR. Failure of orthoclone OKT3 retreatment in a pancreas transplant recipient with antimurine antibody. J Clin Lab Anal 4: 99-101, 1990 Shah BV, Hong CD, First MR. Effect of cyclosporine on fractional excretion of sodium (FENa) in renal transplant patients. Clin Transplant 4: 102-107, 1990 Pesce AJ, Schroeder TJ, First MR. An evaluation of cyclosporine monitoring by nonselective fluorescence polarization immunoassay. Transplant Proc 22: 1171-1174, 1990 Sridhar N, Schroeder TJ, Pesce AJ, First MR. Clinical correlations of cyclosporine HPLC and FDIA levels in renal transplant recipients. First MR, Schroeder TJ. Beware possible interactions between cyclosporine and antimicrobial agents. J Crit Illness 5:891-892, 1990 Kashtan CE, Butowski RJ, Kleppel MR, First MR, Michael AF. Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J Lab Clin Med 116:508-515, 1990 Tchervenkov JI, Munda R, Weiss M, First MR, Alexander JW. Adult respiratory distress syndrome following chronic rejection of a pancreatic allogrant - a case report. Transplantation 50:883-884, 1990 Schroeder TJ, Weiss MA, Smith RD, Stephens GW, Carey M, First, MR. The use of OKT3 in the treatment of acute vascular rejection. Transplant Proc 23:1043-1045, 1991 Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, Munda R, Penn I, Carey M, First MR. Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. Transplant Proc 23:1253-1255, 1991 Schroeder TJ, Weiss MA, Smith RD, Stephens GW, First MR. The efficacy of OKT3 in vascular rejection. Transplantation 51:312-315, 1991 First MR, Schroeder TJ, Alexander JW, Stephens GW, Weiskittel P, Myre SA, Pesce AJ. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51:365-370, 1991 First MR, Schroeder TJ. Solid-organ transplantation in the pediatric population. Clin Transplant 5:132-136, 1991 Schroeder TJ, Ryckman FC, Hurtubise PE, Pedersen SH, Batistreri WF, First MR. Immunological monitoring during and after OKT3 therapy in children. Clin Transplant 5:191-196, 1991 Sridhar NR, Tchervenkov JJ, Weiss MA, Hijazi YM, First MR. Disseminated histoplasmosis in a renal transplant patient: A cause of renal failure several years following transplantation. Am J Kidney Dis 17:719-721, 1991 First MR. The dilemma of organ donation and distribution. J Transplant Coordination 1:60-64, 1991 Schroeder TJ, Pesce AJ, Vine WH, First MR. Cyclosporine monitoring: An update. Am Assoc First MR. Donation and transplantation: Where will we be in 2010? Surgeon General's Workshop on Increasing Organ Donation Washington, D.C., July 8-10, 1991. U.S. Department of Health and Human Services, Public Health Service, pp 15-25 First MR. The organ donation problem. Literature Scan: Transplantation 7:1-2, 1991 Myre SA, Schroeder TJ, Grund VR, Wandstrat TL, Nicely PG, Pesce AJ, First MR. Critical ketoconazole dosage range for cyclosporine clearance inhibition in the dog. Pharmacology 43: 233-241, 1991 First MR. New immunosuppressive drugs. Am J Kidney Dis 19: 3-9, 1992 First MR. Transplantation in the nineties. Presidential address, American Society of Transplant Physicians. Transplantation 53: 1-11, 1992 Schroeder TJ, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First MR, Muth KL. A multicenter study to evaluate a novel assay for quantitation of a soluble interleukin 2 receptor in renal transplant recipients. Transplantation 53:34-40, 1992. First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P. The effect of indomethacin on the febrile response following OKT3 therapy. Transplantation 53: 91-94, 1992 Gorman KJ, First, MR. An economics grand rounds presentation: The economics of renal transplantation. Transplant Surgical Resource Series 5:1-26, 1992 First MR. Future prospects of transplantation. What will happen in the next 20 years? Biomedical Market Newsletter 2:13-16, 1992 Alexander JW, Babcock GF, First, MR, Davies CB, Madden RL, Munda R, Penn I, Fidler JP, Cofer BR, Stephens G, Schroeder TJ, Hariharan S, Cardi M, Manzler A, Cohen L, Mendoza N, Clyne D, Giese F. The induction of immunologic hyporesponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. Transplantation 53:423-427, 1992 Sridhar N, Schroeder TJ, Hariharan S, Pesce AJ, First MR. Influence of concomitant medication on cyclosporine dosage and blood concentrations in renal allograft recipients. Clin Transplantation 6:134-138, 1992 Shield CF, Kahana L, Pirsch J, Vergne-Marini P, First MR, Schroeder TJ, Cohen D, Norman DJ, Monaco A, Martinez A, Dinarello CA, Dehlinger J, Wu SCH, Van Horn A. Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 54:164-166, 1992 Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ. Efficacy of a single pretransplant donor-specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype- mismatched living related donor kidney transplant. Ann Surg 215:618-626, 1992 First MR. New immunosuppressive agents. Literature Scan: Transplantation 8:1-3, 1992 Hariharan S, Schroeder TJ, Carey MA, First MR. Renal transplantation in patients with systemic lupus erythematosus. Clin Transplantation 6:345-349, 1992 Sridhar NR, Munda R, Balakrishnan K, First MR. Evaluation of flowcytometric crossmatching in renal allograft recipients. Nephron 62:262-266, 1992 Sridhar NR, Blanton M, Whitacre L, Balakrishnan K, First MR. Flow cytometric evaluation of cytotoxic peripheral blood lymphocytes in acute renal allograft rejection. J Am Soc Nephrol 3:1220-1226, 1992 Schroeder TJ, First MR, Pouletty C, Hariharan S, Pouletty P. Rapid detection of anti-OKT3 antibodies with the transtat assay. Transplantation 55: 297-299, 1993 Alexander JW, Davies CB, First MR, Cofer BR, Munda R, Madden RL, Hariharan S. Single pretransplant donor - specific transfusion in cadaver and living related donor renal transplantation. Transplant Proc 25:485-487, 1993 First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Safety of long-term cyclosporine-ketoconazole administration and preliminary results of a Madden RL, Munda R, Hariharan S, Alexander JW, First MR. Outcome of cadaver kidneys using nonideal donors. Transplant Proc 25:1568-1569, 1993. Mahoney MC, Racadio JM, Merhar GL, First MR. Safety and efficacy of kidney transplant biopsy: Tru-cut needle vs sonographically guided biopty gun. Am J Roentgen 160:325-326, 1993 First MR, Schroeder TJ, Hariharan S. OKT3-induced cytokine-release syndrome: Renal effects (cytokine nephropathy). Transplant Proc 25 (suppl. 1): 25-26, 1993 First MR, Schroeder TJ, Hariharan S, Weiskittel P. Reduction of the initial febrile response to OKT3 with indomethacin. Transplant Proc 25 (suppl. l):52-54, 1993 Schroeder TJ, Hariharan S, First MR: Antibody response to OKT3 and methods for monitoring. Transplant Proc 25 (suppl. l):77-80, 1993 Alexander JW, First MR, Davies CB, Campbell P, Babcock GF. Donor - Specific transfusion - induced tolerance in animals and man: A therapeutic strategy. Transplant Sci 3:72-75, 1993 First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Cyclosporine-ketoconazole interaction: Long-term follow-up and preliminary results of a randomized trial. Transplantation 55:1000-1004, 1993 Schroeder TJ, Sridhar N, Pesce AJ, Alexander JW, First MR. Clinical correlations of cyclosporine-specifc and - nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity. Ther Drug Monit 15:190-194, 1993 Hariharan S, Schroeder TJ, First MR. Effect of race on renal transplant outcome. Clin Transplant 7:235-239, 1993 Sternberg RI, Baughman RP, First MR. Erythromycin-induced hearing loss in immunosuppressed transplant patients. Clin Transplant 7:269-272, 1993 Madden RL, Schroeder TJ, Schleuter KT, Davies CB, Myre SA, Hariharan S, Alexander JW, First MR. Ketoconazole fails to increase cyclosporine G blood levels in Lewis rats. Pharmacol Comm 3:275-281, 1993 Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of adverse effects associated with immunosuppressive therapy. Drug Safety 9:104,131, 1993 First MR. Long-term complications after transplantation. Am J Kidney Dis 22:477-486, 1993 Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR. Prednisone withdrawal in HLA identical and one haplotype - matched live-related donor and cadaver renal transplant recipients. Kidney Int 44 (suppl 43):30-35, 1993 Sternberg RI, Baughman RP, Dohn MN, First MR. Utility of bronchoalveolar lavage in assessing pneumonia in immunosuppressive renal transplant recipients. Am J Med 95:358-364, 1993 Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 72:2186-2189, 1993 Myre SA, Schroeder TJ, Pesce AJ, Mechlinski W, First MR. Influence of cyclosprine A or ketoconozole blood levels and oral clearance in the dog. Pharmacol Comm 4:49-53, 1993 Anderson P, Schroeder TJ, Hariharan S, First MR. Incidence of posttransplant lymphoproliferative disease in OKT3-treated renal transplant recipients. Clin Transplant 7:582-585, 1993 First MR. Renal allograft survival after 1 and 10 years: comparison between precyclosporin and cyclosporin data. Nephrol Dial Transplant 9:90-97, 1993 Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 23:138-147, 1994 Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 4:S10-16, 1994 First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 4:S30-S36, 1994 Gruber SA, Stephanian E, Dunn DL, First MR. A complicated case of skin cancer in a renal allograft recipient. Transplant Sci 4:17-19, 1994 166. Schroeder TJ, First MR. Cytomegalovirus infection and the role of ganciclovir prophylaxis in transplant Madden RL, Schroeder TJ, Alexander JW, First MR. Single dose OKT3: Adverse effects, pharmacokinetics, and anti-OKT3 antibody response. Transplant Sci 4:112-114, 1994 Schroeder TJ, Michael AT, First MR, Hariharan S, Bhat G, Hanto DW, Ryckman FC, Balistreri WF. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther Drug Monit 16:361-367, 1994 Masroor S, Schroeder TJ, Michler RE, Alexander JW, First MR. Monoclonal antibodies in organ transplantation: An overview. Transplant Immunol 2:176-189, 1994 First MR. Ten years of cyclosporin A. Literature Scan: Transplantation 10:1-3, 1994 Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant patients. Transplant Proc 26:2787-2790, 1994. Muirhead N, Cattran DC, Zaltzman J, Jindal K, First MR, Boucher A, Keown PA, Munch LC, Wong C. Safety and efficacy of recombinant human erythropoietin in correcting anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 5:1216-1222, 1994 Schroeder TJ, Hariharan S, First MR. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc 27: 837-839, 1995 First MR, Combs CA, Weiskittel P, Miodovnik M. Lack of effect of pregnancy on renal allograft survival or function. Transplantation 59: 472-476, 1995 Sketris I, Yatscaff R, Keown P, Canafax DM, First MR, Holt DW, Schroeder TJ, Wright M. Optimizing the use of cyclosporine in renal transplantation. Clin Biochem 28:195-211, 1995 First MR. Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr Nephrol 9:S40-42, 1995 Skannal DG, Dungy-Poythress LJ, Miodovnik M, First MR. Pregnancy in a combined liver and kidney transplant recipient with type I primary hyperoxaluria. Obstet Gynec 86:641-643, 1995 Schroeder TJ, First MR, Gaber AO. Monitoring and management of immunosuppression in pediatric transplant patients. Clin Immunother 4:425-444, 1995 Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Conversion from cyclosprine to tacrolimus after pancreas transplantation. Transplant Proc 27:2981-2982, 1995 Peddi VR, Hariharan S, Munda R, Schroeder TJ, First MR. Impact of ganciclovir prophylaxis on cytomegalovirus infecion in cadaveric kidney vs combined kidney and pancreas transplantation. Transplant Proc 27:3076-3077, 1995 El-Ghoroury M, Hariharan S, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Comparison between methylprednisolone and OKT3 treatment for the first acute rejection episode in combined kidney and pancreas transplant recipients. Transplant Proc 27:3133-3134, 1995 Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant 10:20-23, 1996 Rossi S, Schroeder TJ, Muth K, Hanto D, Munda R, Hariharan S, First MR, Ryckman F, Balistreri W. Serial monitoring of soluble interleukin-2 receptor as a rapid marker of cytomegalovirus infection and response to therapy. Clin Transplant 10:45-50, 1996 First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis J, Armenti VT. Cyclosporine bioavailability dosing implication and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 10:55-59, 1996 Viero RM, First MR, Cavallo T. Detection of Epstein-Barr virus message in renal allografts. Transplantation 61:321-323, 1966 Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant 10:160-165, 1996 Hariharan S, Alexander JW, Schroeder TJ, First MR. Outcome of cadaveric renal transplantation by induction treatment in the cyclospsorine era. Clin Transplant 10:186-190, 1996 Hariharan S, Munda R, Cavallo T, Demmy AM, Schroeder TJ, Alexander JW. Rescue therapy with tacrolimus after combined kidney/pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 61:1161-1165, 1996 First MR, Schroeder TJ. The relationship between cyclosporin bioavailability, clinical outcome and resource utilization in renal transplant recipients. Perspectives 1:8-10, 1996 Schroeder TJ, Shah M, Hariharan S, First MR. Increased resources are required in patients with low cyclosporine bioavailability. Transplant Proc 28:2151-2155, 1996 Skannal DG, Miodovnik M, Dungy-Poythress LJ, First MR. Successful pregnancy after combined renal-pancreas transplantation: A case report and literature review. Am J Perinatol 13:383-387, 1996 Pescovitz MD, Brayman K, Brenner D, Brinker K, Burke J, Canafax D, Chan L, First MR, Greenstein S, Gruber S, Lewis R, Metzger R, Mulgoankar S, Neylan J, Perez R, Peterson J, Shapiro R, Vanderwerf B, Wright C. Conversion from Sandimmune to Neoral in stable renal transplant patients. Transplant Proc 28:2196-2198, 1996 Cavallo T, First MR. "Recurrence" of cyclosporine nephrotoxicity in a heart transplant recipient. Am J Kidney Dis 28:466-468, 1996 Hariharan S, Smith RD, Viero R, First MR. Diabetic nephropathy after renal transplantation. Transplantation 62:632-635, 1996 Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 10:414-419, 1996 Peters TG, Kittur DS, McGaw LJ, First MR, Nelson EW. Organ donors and non donors. An American dilemma. Arch Int Med 156:2419-2424, 1996 First MR. Living unrelated renal donors. Literature Scan: Transplantation 12:1-2, 1996 Hariharan S, Alexander JW, Schroeder TJ, First MR. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. Clin Transplant 10:538-541, 1996 199. First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: Potential applications in organ transplantation. Am J Kidney Dis 29:303-317, 1997 First MR. Controversies in organ donation: Minority donation and living unrelated renal donors. First MR. Cadaveric organ procurement - An overview of two aspects: Donor hospital networks, and minority donation. Transplant Proc 29: 70-72, 1997 Peddi VR, Dean DE, Hariharan S, Cavallo T, Schroeder TJ, First MR. Proteinuria following renal transplantation: Correlation with histopathology. Transplant Proc 28: 101-103, 1997 Gaber LW, Moore LW, Gaber AO, First MR, Guttmann RD, Pouletty P, Schroeder TJ. A multicenter report on the utilization of the Banff grading in acute renal rejection. Transplant Proc 29: 184-185, 1997 Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS, Adams M, Bennett WM, Bowen PA, Burdick J, First MR, Inokuchi S, Jensik SC, Kahana L, Laskow D, Light JA, Mendez R, Neylan JF, Shield CF, Stuart FP, Vergne-Marini P. FK 506 in kidney transplantation: Results of the U.S.A. randomized comparative phase III study. Transplant Proc 29: 304-305, 1997. El-Ghoroury M, Hariharan S, Peddi VR, Munda R, Schroeder TJ, Demmy AM, Alexander JW, First MR. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. Transplant Proc 29: 649-651, 1997 Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. Transplant Proc 29: 652-653, 1997 Stratta RJ, First MR, Egidi F, Corry RJ, Johnson CP, Marsh CL, Burke GW, Gruessner RWG, Sutherland DER, Kaufman D, Bartlett ST, Sollinger HW, Boudreany JP, Benedetti E. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: A multicenter report. Transplant Proc 29: 654-655, 1997 Schroeder TJ, Levy R, Pouletty P, First MR. A generic cyclosporine develoment program. Transplant Proc 29: 1235-1238, 1997 First MR. Xenotransplantation: Social, ethical, religious, and political issues. Kidney Int 51 (suppl 58): 46-47, 1997 Peddi VR, Hariharan S, Schroeder TJ, First MR. Impact of ganciclovir prophylaxis on cytomegalovirus infection n recipients of cadaveric renal allografts. Nephron 76:49-55, 1997 Peddi VR, First MR. Primary care of patients with renal transplants. Med Clin North Am 81:767-784, 1997 Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, Adams MB, Bennett WM, Bowen PA, Burdick J, Rascusen L, First MR, Inokuchi S, Jensik SC, Kahana L, Laskou D, Light JA, Mendez R, Neylan JF, Shield CF, Stuart FP, Vergne-Marini P, Solez K, Facklam D, Kershner R. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63:977-983, 1997 First MR. Expanding the donor pool. Semin Nephrol 17:373-380, 1997 Valente JF, Hariharan S, Peddi VR, Schroeder TJ, Ogle CK, Alexander JW, First MR. Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era. Gruessner RWG, Gruessner A, Drangstveit MB, Sutherland DER, Egidi F, Corry R, Starzl T, Burke G, Stratta R, Marsh C, Perkins J, Munda R, First MR, Johnson C, Benedetti E, Kaufman D, Brayman K, Fabrega M, Martin M, Boudreaux P, Frey D, Stock P, Melzer J. Tacrolimus in pancreas transplantation: A multicenter analysis. Clin Transplant 11:299-312, 1997 Rahusen F, Munda R, Hariharan S, First MR, Demmy A. Combined kidney-pancreas and parathyroid transplantation: A case report. Clin Transplant 11:341-343, 1997 217. Daoud AJ, Schroeder TJ, Kano J, Horn HR, Berger-Moran H, First MR. The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection. Transplant Proc 29 (Suppl 7A):18-20, 1997 Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection. Transplantation 64:1428-1432, 1997 Whiting JF, Golconda M, Smith R, O’Brien S, First MR, Alexander JW. Clinical and economic outcomes of expanded criteria donors in renal transplantation. Transplant Proc 29:3258, 1997 First MR. The donor supply. Transplant Proc 29:3299-3000, 1997 Whiting JF, Golconda M, Smith R, O’Brien S, First MR, Alexander JW. Economic costs of expanded criteria donors in renal transplantation. Transplantation 65:204-207, 1998 Golconda MS, Whiting JF, Smith R, Hayes R, Alexander JW, First MR. Long-term outcome of kidney transplantation from expanded criteria donors: A single center experience. Transplant Proc 29:3379-3381, 1997 Gaber LW, Moore LW, Gaber AD, First MR, Guttmann RD, Pouletty P, Schroeder TJ, Soulillou J-P. Utillity of standardized histological classification in the management of acute rejection. Transplantation 64:376-380, 1998 224. Neylan JF, Adams MB, Bennett WB, Bowen AB, Mulloy L, Burdick J, Filo RS, First MR, Inokuchi S, Jensik SC, Kahana L, Laskow D, Deierhoi M, Light JA, Mendez R, Miller J, Pirsch JD, Shield CF, Stuart FP, Vergne-Marini P, Vincenti F, Solez K, Racusen L, Mekki Q, Facklam D. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 65:515-523, 1998. First MR. Clinical applications of immunosuppressive agents in renal transplantation. Surg Clin North Am 78:61-76, 1998 Peddi VR, Kamath S, Schroeder TJ, Munda R, First MR. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients. Transplant Proc 30:285-287, 1998 Peddi VR, Demmy AM, Munda R, Alexander JW, First MR. Tacrolimus eliminates actue rejection as a major complication following combined kidney and pancreas transplantation. Transplant Proc 30:509-511, 1998 228. First MR, Peddi VR. Complications occurring after transplantation. Literature Scan 14:1-3, 1998 229. First MR. Who should fund chronic rejection trials? Graft 1 (suppl 2):107-109, 1998 Hariharan S, Peddi VR, Savin VJ, Johnson CP, First MR, Roza AM, Adams MB. Recurrent and de novo renal diseases after renal transplantation: A report from the renal allograft recurrent disease registry. Am J Kidney Dis 31:928-931, 1998 First MR, Gaber AO, Guffmann RD, Moore LW, Schroeder TJ, Soulillon JP. Efficacy endpoints conference on acute rejection in renal transplantation: Introduction. Am J Kidney Dis 31 (suppl 1):1-2, 1998 Al-Awwa IA, Hariharan S, First MR. Importance of allograft biopsy in renal transplant recipients: Correlation between clinical and histologic diagnosis. Am J Kidney Dis 31 (suppl 1): 15-18, 1998 Schroeder TJ, Moore LW, Alsina A, Cantarovich D, Chapman J, Charpentier B, Cohen D, First MR, Gaber O, Glotz D, Guttmann R, Halloran P, Hunsicker L, Koene R, Legendre C, Leichtman A, Margreiter R, Matas A, Ponticelli C, Remuzzi G, Woodle S. Efficacy endpoints conference on acute rejection in kidney transplantation: Summary report of the database. Am J Kidney Dis 31 (suppl1):31-39, 1998 Guttmann RD, Soulillon JP, Moore LW, First MR, Gaber AO, Pouletty P, Schroeder TJ. Proposed consensus for definitions and endpoints for clinical trials of acute renal transplant rejection. Am J Kidney Dis 31 (suppl 1):40-46, 1998 Jensik SC, Adams MB, Bennett WM, Bowen PA, Malloy L, Burdick J, Filo RS, First MR, et al. Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 30:1216-1218, 1998 Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR. Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection. Transplant Proc 30:1178-1180, 1998 Peddi VR, Munda R, Demmy AM, Alexander JW, First MR. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. Transplant Proc 30:1541-1543, 1998 First MR. New solutions to overcome the organ donor shortage. Graft 1:117-118, 1998 Peddi VR, Whiting J, Weiskittel PD, Alexander JW, First MR. Characteristics of long-term renal transplant survivors. Am J Kidney Dis 32:101-106, 1998 Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahana L, Steinberg S, Woodle ES, Chan L, Ham JM, Stratta RJ, Wahlstrom E, Lamborn KR, Horn HR, Moran HB, Pouletty P, Schroeder TJ. Results of the double -blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Kaplan AJ, Valente JF, First MR, Demmy AM, Munda R. Early operative intervention for urologic complications of kidney-pancreas transplantation. World J Surg 22:890-894, 1998 Shah MB, Martin JE, Schroeder TJ, First MR. Evaluation of the safety and tolerability of Neoral and Sandimmune: A Meta-analysis. Transplant Proc 30:1697-1700, 1998 First MR, Weiskittel P, Burton M, Shah M, Dreyer D, Fleck C, Bey R, Peddi R, Canafax D, Schroeder TJ. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. Transplant Proc 30:1701-1705, 1998 244. Pescovitz MD, First MR. Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion. Transplant Int 11 (Suppl 1):594-597, 1998 First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant Proc 30:2768-2770, 1998 Peddi VR, Kamath S, Munda R, Demmy AM, Alexander JW, First MR. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Clin Transplant 12:401-405, 1998 Peddi VR, First MR. Screening of patients with pre-transplant malignancies. Curr Opin Organ Transplant 3:78-81, 1998 First MR. The state of present and future immunosuppressive therapy in re nal transplantation. First MR, Alloway R, Schroeder TJ. Development of Sang-35: A cyclosporine formulation bioequivalent to Neoral. Clin Transplant 12:518-524, 1998 First MR, Weiskittel P, Shah M, Peddi VR, Canafax D, Schroeder TJ. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation using a dose-adjusted method. Transplant Proc 30:3955-3957, 1998 Shah MB, Martin JE, Schroeder TJ, First MR. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Transplant Proc 30:4048l-4053, 1998 Fleck PR, Schroeder TJ, Dauod AJ, Peddi VR, First MR. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. Transplant Proc 30:4070-4072, 1998 253. Daoud AJ, Schroeder TJ, Shah M, Hariharan S, Peddi VR, Weiskittel P, First MR. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine, and tacrolimus. Transplant Proc 30:4079-4081, 1998 Baker GM, Martin JE, Jang R, Schroeder TJ, Armistead JA, Myre S, First MR. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary renal transplantation. Transplant Proc 30:4082-4084, 1998 First MR. Immunosuppressive therapy strategies in the immunological high-risk renal transplant recipients. Organs Tissues 2:83-87, 1998 Woodle ES, First MR, Gaber AO, Gaston RS, Mendez R, Mulloy LL, Kano JM, Schroeder TJ. Twelve month outcome of the double blind, randomized multicenter rejection trial of thymoglobulin vs Atgam in renal transplants. Graft 2 (suppl 1):24-27, 1999 Shah MB, Martin JE, Schroeder TJ, First MR. Va lidity of open labeled versus blinded trials: A meta-analysis comparing Neoral and Sandimmune. Transplant Proc 31:217-219, 1999 258. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F, Ge orge V. Recurrent and de novo glomerular diseases after renal transplantation: A report from The Renal Allograft Disease Registry. Transplant Proc 31:223-224, 1999 First MR. Immunologically high-risk recipient strategies. Transplant Proc 31:243-246, 1999 Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR. Mycophenolate mofetil - induced colonic ulceration in renal transplant recipient. Transplant Proc 31:272-273, 1999 Khosla UM, Martin JE, Baker GM, Schroeder TJ, First MR. One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Transplant Proc 31:274-275, 1999 First MR, Weiskittel P, Burton ML, Shah MB, Dreyer D, Peddi VR, Canafax DM, Schroeder TJ. Nine-month follow-up of SangCyA (Sang-35) in kidney transplant patients after conversion from Sandimmune. Transplant Proc 31:324-325, 1999 Gaston R, Alloway RR, Gaber AO, Rossi SJ, Schroeder TJ, Irish WD, Canafax DM, First MR. Pharmacokinetic and safety evaluation of SangCyA vs Neoral or Sandimmune in stable renal transplant recipients. Transplant Proc 31:326-327, 1999 Peddi VR, Munda R, Demmy AM, First MR. Long-term outcome in simultaneous kidney and pancreas recipients with functioning allografts at 1-year post transplantation. Transplant Proc 31:608-609, 1999 Peddi VR, Schroeder TJ, Weiskittel P, First MR. Graft outcome in patients with biopsy-proven chronic renal allograft rejection. Transplant Proc 31:1308-1309, 1999 Whiting JF, Zavala EY, Alexander JW, First MR. The cost-effectiveness of transplantation with expanded donor kidneys. Transplant Proc 31:1320-1321, 1999 Shah MB, Schroeder TJ, First MR. Guidelines for immunosuppression management and monitoring after transplantation in children. Transplant Rev 13:83-97, 1999 Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 15:317-337, 1999 First MR. Post-transplant management in the 21st century: New challenges in clinical care. Graft 2 (suppl 2): 24, 1999 First MR. Clinical definition of graft rejection: Are the pathologic criteria adequate to identify the clinical problem? Graft 2 (suppl 2):28-30, 1999 Lowance D, Newmayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee K, Griffith P, Kletzmayr J, Besse T, Lalaoui H, Salmela K, Besthoux F, Kreis H, Lebranchu Y, Hauser I, Castagneto M, Fauchabl P, Hickey D, Noreiga A, Leski M, Altmann P, Lee H, Rodgers R, Conti D, DeVault G, Holman J, Drummer S, Van Buren D, Dunn D, First R, Gaber AO, Alloway R, Vosatka K, Silibovsky R, Zuckerman J, VanSickler J, Colthart J, Popp F, Wind J, Grant D. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340:1462-1470, 1999 272. Shah MD, Martin JE, Schroeder TJ, First MR. The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral and Sandimmune. Transplantation 67:1411-1417, 1999 Schroeder TJ, First MR, Alloway RR, Pan S-H, Gaber AO, Lopez RR, Fisher RA, Irish WD, Canafax DM, Pouletty P. Review of cyclosporine pharmacokinetic trials in healthy volunteers and kidney and liver transplant recipients: Sang CyA versus Neoral and Sandimmune. Transplant Rev 13:128-134, 1999 Brennan DC, Barbetto R, Burke J, Brayman K, Greenstein S, Chang T, Boinker K, Chan L, Conti D, First MR, Lewis R, Matas A, Metzger R, Mulgoankal S, Neylan J, Perez R, Pescovitz M, Tischer C, Vanderweof B, Wright C. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. Kidney Int 56:685-691, 1999 Peddi VR, First MR. Early post-transplant care of renal transplant recipients. Semin Dial 12:320-328, 1999 Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincent F, George V. Recurrent and de novo glomerular disease after renal transplantation. Transplantation 68:635-641, 1999 Dean DE, Kamath S, Peddi VR, Schroeder TJ, First MR, Cavallo T. A blinded retrospective analysis of renal allograft pathology using the Banff Schema. Implications for clinical management. Transplantation 68:642-645, 1999 First MR, Peddi VR. Recurrent disease after renal transplantation. Literature Scan: Transplantation 15:4-5, 1999 Alexander JW, Light JA, Donaldson LA, Delmonico FL, Drethelm AG, Wilkinson A, Rosenthal JT, Thistlethwaite JR, Hunsicker LG, Matas AJ, First MR, Reinsmoen NL, Rose SM. Evaluation of pre and post-transplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Transplantation 68:1117-1124, 1999 Canafax DM, Irish WD, Moran HB, Squiers E, Levy R, Puoletty P, First MR, Christians U. An individual approach to compare the intrasubject variability of two cyclosporin formulations, SangCya and Neroal. Pharmacology 59:78-88, 1999 First MR, Gaber AO, Olyaei A. Drug substitution in transplantation. Am J Kidney Dis 34:1-2, 1999 (letter). Penn I, First MR. Merkel’s cell carcinoma in organ recipients: Report of 41 cases. Transplantation 68:1717-1721, 1999 First MR, Alloway RR, Fisher RA, Pan S-H, Lopez R, Renlund D, Schnitzler M, Gaber AO. Generic drug substitution in transplantation: Examples from the epic of cyclosporine development. Dial Transplant 29:260-267, 2000 Christians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Therapy Drug Monit 22:330-345, 2000 Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol 79:220-224, 2000 286. First MR. What is the role of recently-approved immunosuppressive agents? An update. Contemp Dial First MR. Hepatitis C virus infection in the renal transplant recipient. Nephrol Dial Transplant 15 (suppl 8):60-64, 2000 Whiting JF, Woodward R, Zavala EY, Cohen DS, Martin JE, Singer GG, Lowell JA, First MR, Brennan DC, Schnitzler MA. Economic cost of expanded criteria donors in cadaveric renal transplantation: Analysis of Medicare payments. Transplantation 70:755-760, 2000 Whiting J, Evans R, First MR, Keown P, Martin J, Pinson PW, Schnitzler M, Schroeder T, Whiting J, Zavala E. Standards for economic and quality of life studies in transplantation. Transplantation 70:1115-1121, 2000 Roy-Chaudhury P, Alexander JW, First MR, Peddi VR, Munda R, Cavallo T. Immediate allograft dysfunction due to atheroembolic disease. Am J Kidney Dis 2:423-426, 2001 First MR, The organ shortage and allocation issues. Transplant Proc 31:806-810, 2001 Phillips AL, Walker EL, Martin JE, First MR, Hanto DW, Whiting JF. Quality of life as a predictor of morbidity, mortality, and resource utililzation after transplantation. Transplant Proc 33:1886, 2001 Boyd SR, Martin JE, First MR, Whiting, JF. Health utililty scores following renal transplantation. Transplant Proc 33:1900, 2001 Martin JE, Shireman TI, First MR, Whiting JF. Quality of life following solid organ transplantation in Medicaid beneficiaries. Transplant Proc 33:1909, 2001 295. First MR. Post-transplant diabetes mellitus. Literature Scan: Transplantation 17:4-5, 2001 296. First MR. Tailoring immunosuppressive therapy based on donor and recipient risk factors. Transplant Proc 33:2207-2211, 2001 Kelly BS, Alexander JW, Dreyer D, Greenberg NA, Ericson A, Whiting JF, Ogleck, Babcock GF, First MR. Oral arginine improves blood pressure in renal transplant patients. J Parent Ent Nutr 25:194-202, 2001 Peddi VR, First MR. Recent advances in immunosuppressive therapy for reanl transplantation. Semin Dial 14:218-222, 2001 First MR. Interactive Grand Rounds Case 1: Persistent acute rejection after kidney transplantation. Transplantation 71:1697-1698, 2001 First MR. Interactive Grand Rounds Case 2: Post-transplant diabetes mellitus in renal transplantation. Transplantation 71:1872-1873, 2001 First MR. Interactive Grand Rounds Case 3: Cardiovascular disease in renal transplantation. Transplantation 72:556-557, 2001 First MR. Interactive Grand Rounds Case 4: Post-transplant lymphoproliferative disease in renal transplantation. Transplantation 72:754-755, 2001 First MR. Interactive Grand Rounds Case 5: Recurrent disease in transplantation. Transplantation 72:979, 2001 First MR. Interactive Grand Rounds Case 6: Benefits and risks of OKT3 treatment in renal transplantation. Transplantation 72:1177-1178, 2001 First MR. Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. Transplantation 72 (suppl): S20-S24, 2001 Buell JF, Trofe J, Hanaway MJ, Lo A, Rosengard B, Rilo H, Alloway R, Beebe T, First MR, Woodle ES. Transmission of donor cancer into cardiothoracic recipients. Surgery 130:660-668, 2001 Pesce AJ, First MR. Proteinuria - An Integrated Review. Marcel Dekker, Inc., New York and Basel, 1979 First MR, Pollak VE. Renal insufficiency in the diabetic patient with heart disease. In, Clinical Cardiology and Diabetes. Scott RC (Ed.), Vol. III, Part 2, Futura Publishing Co., Inc., Mount Kisco, New York, 1981, pp 63-92 First MR. Chronic Renal Failure. Pathophysiology, Clinical Manifestations, and Management. Medical Examination Publishing Co., Inc., Flushing, New York, 1982 First MR. Renal function. In, Clinical Chemistry. Kaplan LA, Pesce AJ (Eds.), C. V. Mosby & Co., St. Louis, Missouri, 1984, pp 403-419 First MR. Post-traumatic acute renal failure. In, Common Problems in Trauma and Critical Care. Hurst JM (Ed.), Year Book Medical Publishers, Inc., Chicago, 1987, pp 407-412 First MR. The use of laboratory tests in renal disease, acid-base and electrolyte disorders. In, Methods in Clinical Chemistry. Pesce AJ, Kaplan LA (Eds.), C. V. Mosby & Co., St. Louis, Missouri, 1987, pp 2-4 First MR. Blood tranfusion and immunosuppression. In, Southeastern Organ Procurement Tissue Typing Manual. Macqueen JM (Ed.), Chapter 8, 1987, pp 8:1 - 8:6 Alexander JW, First MR, Munda R, Fidler JP, Penn I, Weiskittel P, Collins J, Waymack JP. The transfusion effect. In, Chronic Renal Failure and Transplantation. Haberal MA (Ed.), Turkish Transplantation and Burn Foundation, Ankara, Turkey, 1987, pp 185-193 First MR, Pollak VE. Pregnancy and renal disease. In, Diseases of the Kidney. Schrier RW, Gottschalk CW (Eds.), 4th Edition, Vol. III, Chapter 83, Little Brown & Co., Boston, 1988, pp 2533-2559 10. First MR. The evaluation and medical management of the immunosuppressed host who requires operative intervention. In, Surgery in the Immunocompromised Host, Problems in General Surgery. Pollak R, Nyhus LM (Eds.), Vol. 6, Number 3, J. P. Lippincott & Co., Philadelphia, 1989, pp 388-394 11. First MR, Renal function. In, Clinical Chemistry: Theory, analysis and correlation. Second edition. Kaplan LA, Pesce AJ (Eds.), C.V. Mosby Company, St. Louis, Missouri, 1989, pp 346-358 12. Schroeder TJ, Myre SA, Pesce AJ, First MR. Practical aspects of cyclosporine use and monitoring at the University of Cincinnati Medical Center. In, Advances in Therapeutic Drug Monitoring. Tanaka K, Pippenger CE, Mimaki T, Walson PD, Ohgitani S (Eds.), Enterprise, Tokyo, 1990, 13. First MR. Pre-transplant evaluation and preparation of donors and recipients. In, The Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), B. C. Decker, Inc., Philadelphia, 1991, pp 820-825 14. First MR. Annual review of transplantation. In, Clinical Transplants 1990. PI Terasaki (Ed.) UCLA Tissue Typing Laboratory, Los Angeles, 1991, pp 357-373 15. Schroeder TJ, First MR, Penn I. Multi-organ transplant experience with OKT3 and strategies for use at the University of Cincinnati Medical Center. In, Organ Transplantation 1990. Abouna GM, Kumar MSA, White AG (Eds.), Kluwer Academic Publishers, Dordrecht, Netherlands, 1991, pp 91-100 16. Alexander JW, First MR, Hariharan S, Penn I, Schroeder TS, Ryckman F, Munda R, Bhat G, Bolce R. Recent contributions to transplantation at University of Cincinnati. In, Clinical Transplants, 1991. PI Terasaki, JM Cecka (Eds.) UCLA Tissue Typing Laboratory, Los Angeles, 1992, pp 159-178 17. First MR, Pollak VE. Pregnancy and renal disease. In, Diseases of the Kidney. Schrier RW, Gottschalk CW (Eds.), 5th Edition, Vol. III, Chapter 83, Little Brown & Co., Boston, 1993, pp 2287-2310 18. Hariharan S, Schroeder TJ, First MR. Cytomegalovirus infection after renal transplantation. In, Asian Nephrology - Proceedings of the Fifth Asian Pacific Congress of Nephrology. Chugh KS (Ed.), Oxford University press, Delhi, 1994, Chapter 77, pp 689-694 19. Hariharan S, Schroeder TJ, First, MR. Cyclosporine A drug interactions. In, Asian Nephrology - Proceedings of the Fifth Asian Pacific Congress of Nephrology. Chugh KS, (Ed.), Oxford University Press, Delhi, 1994, Chapter 85, pp 748-754. 20. First MR. Pretransplant evaluation and preparation of donors and recipients. In, The Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (Eds.), 2nd edition, Mosby-Year Book, Inc., St. Louis, 1995, pp 805-810 21. Johenning AR, First MR. Is chronic renal disease a contraindication to pregnancy? In, International Yearbook of Nephrology Dialysis Transplantation. Andreucci VE, Fine LG (Eds.), Oxford University Press, Oxford, 1995, pp 35-44 22. First MR, Schroeder TJ. The relationship between cyclosporin bioavailability, clinical outcome and resource utilization in renal transplant recipients. In, Rational use of Neoral. R. Johnson (Ed.), The Royal Society of Medicine Press Limited, London, 1996, pp 5-13. 23. First MR. Clinical diagnosis of renal allograft rejection. In, Solid Organ Transplant Rejection: Mechanisims, Pathology, and Diagnosis. Solez K, Racusen LC, Billingham ME (Eds.), Marcel Dekker, Inc., New York, 1996, pp 431-443 24. First MR. Renal Function. In, Clinical Chemistry: Theory, analysis and correlation. Third edition. Kaplan LA, Pesce AJ (Eds.), C.V. Mosby Company, Chicago, Illinois, 1996, pp 484-504 25. Schroeder TJ, Rossi SJ, Schleuter KT, First MR. Laboratory evaluation of the transplant recipient and donor. In, Clinical Chemistry: Theory, analysis and correlation. Third edition. Kaplan LA, Pesce AJ (Eds.), C.V. Mosby Company, Chicago, Ilinois, 1996, pp 1004-1116 26. First MR. The role of polyclonal and monoclonal antibodies in organ transplantation. In, Current Immunosuppression: An Update. NS Hakim (Ed.), The Royal Society of Medicine Press Limited, London, 1997, pp 7-14 27. First MR. Immunosuppression and treatment of rejection. In, Therapy of Renal Diseases and Related Disorders. Third edition. Suki WN, Massry SG (Eds.), Kluwer Academic Publishers, Boston, 1997, pp 1107-1137 28. First MR. The evaluation and preparation of donors and recipients for renal transplantation. In, Therapy in Nephrology and Hypertension. A companion to Brenner and Rector's The Kidney. Brady HR, Wilcox CS (Eds.), W. B. Saunders Company, Philadelphia, PA, 1998, pp 603-607. 29. Peddi VR, First MR. Medical complications of kidney transplantation. In, Dialysis and Transplantation. A companion to Brenner and Rector’s The Kidney. Owen BF, Pereira BJG, Sayegh MH (Eds.), W. B. Saunders Company, Philadelphia, PA, 2000, pp 595-612. 30. Roy-Chaudhury P, Whiting JF, Miller MA, Reaves A, Denman D, Munda R, Heffelfinger SC. Neointimal hyperplasia and hemodialysis access dysfunction: A pathogenetic role for cytokines, matrix proteins, and specific cell types. In, Vascular Access for Hemodialysis. Henry ML (Ed.), W. L. Gore and Associates, Inc., Precept Press, 2000, pp 45-53. 31. Peddi VR, First MR. Antilymphocyte antibodies. In, Textbook of Nephrology, Massry SG, Glassock RJ (Eds.), 4th edition, Lippincott Williams and Wilkins, 2001, pp 1640-1646 32. Peddi VR, First MR. Diagnosis and treatment of renal dysfunction episodes. In, Primer on Transplantation. Norman DJ, Turka LA (Eds.), 2nd edition, American Society of Transplantation, 2001, pp 459-466 *1. DIPYRIDAMOLE (PERSANTIN) AND WARFARIN IN THE TREATMENT OF GLOMERULONEPHRITIS 2. THE EFFECT OF HUMAN LIGHT (KAPPA) CHAINS OF FUNCTION AND MORPHOLOGY OF THE RAT Clyne DH, Brendstrup L, First MR, Pesce AJ, Levy ME, and Pollak VE Proceedings of the annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, 1973. Abstract 68, J Clin Invest 52: *3. INTERSTITIAL NEPHRITIS: CLINICAL AND PATHOLOGIC OBSERVATIONS AND POSSIBLE 4. INJECTION OF HUMAN KAPPA CHAIN IN THE RAT: INDUCTION OF TUBULAR PROTEINURIA AND Clyne DH, Brendstrup L, First MR, Pirani CL, Pesce AJ, and Pollak VE Proceedings of 6th annual meeting of the American Society of Nephrology 5. PROTEINURIA FOLLOWING RENAL TRANSPLANTATION Sethi KK, Pesce AJ, First MR, Hsu MA, Alexander JW, and Pollak VE Proceedings of 7th annual meeting of the American Society of Nephrology *6. FULMINANT PNEUMOCOCCAL SEPSIS IN SPLENECTOMIZED RENAL ALLOGRAFT RECIPIENTS McEnery PT, Flanagan J, First MR, and Laver MD Proceedings of 8th annual meeting of the American Society of Nephrology 7. ALBUMIN EXCRETION BY THE KIDNEY: EFFECTS OF OSMOTIC DIURESIS Patel VB, First MR, Pesce AJ, and Pollak VE 8. PULMONARY INFECTIONS IN RENAL TRANSPLANT PATIENTS Munda R, Alexander JW, Fidler JP, First MR, and Gartside P Association for Academic Surgeons, 1976 Munda R, Alexander JW, Fidler JP, First MR, and Miller S Association of International Transplant Surgeons, 1976 *10. HYPOTHERMIC PULSATILE PERFUSION AND TRANSPLANTATION OF Munda R, Miller JC, Alexander JW, First MR, and Fidler JP International Transplantation Society, New York, 1976 *11. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS Munda R, Alexander JW, Fidler JP, and First MR Clinical Dialysis and Transplant Forum, Washington, D.C., p. 13, 1976 12. EFFECT OF VOLUME EXPANSION AND OSMOTIC DIURESIS ON RENAL ALBUMIN EXCRETION First MR, Patel VB, Sloan DE, Pesce AJ, and Pollak VE 13. MANAGEMENT OF AZATHIOPRINE DOSAGE DURING ACUTE TUBULAR NECROSIS FOLLOWING Proceedings of the 9th annual meeting of the American Society of *14, PRE-ECLAMPSIA WITH THE NEPHROTIC SYNDROME Proceedings of the 9th annual meeting of the American Society of 15. DEMONSTRATION OF CIRCULATING IMMUNE COMPLEXES IN RELATION TO REJECTION EPISODES Ooi YM, Ooi BS, Vallota EH, First MR, and Pollak VE Proceedings of the 9th annual meeting of the American Society of *16. ERYTHROCYTE SPERMINE DEFICIENCY AND THE ANEMIA OF CHRONIC RENAL FAILURE Denton DD, First MR, Glazer HS, Smith FG, Edwards BK, and Hogg JW American Society of Hematology, Boston, 1976 17. SURVEY OF FAMILY ATTITUDES TOWARDS ANATOMICAL DONATION FOLLOWING DEATH AND Schott DL, Hartman MP, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, 1977 *18. THE VALUE OF URINE CYTOLOGY IN RENAL TRANSPLANTATION Fidler JP, Dajani FA, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, 1977 *19. CORRECTION OF ERYTHROID POLYAMINE METABOLISM BY RENAL TRANSPLANTATION Denton DD, First MR, Glazer HA, Smith FG, and Edwards BK American College of Physicians Regional Meeting, September, 1977 *20. BENEFICIAL EFFECT OF PRIOR SPLENECTOMY ON GRAFT SURVIVAL IN CADAVERIC RENAL Laver MC, Pollak VE, First MR, Clyne DH, and Alexander JW Proceeding of the 10th annual meeting of the American Society of Nephrology, Washington, D. C., 1977, p. 81 *21. TWELVE YEAR SURVIVAL IN A PATIENT WITH WEGENER'S GRANULOMATOSIS: TREATMENT WITH Proceedings of the Pan-American Congress of Pheumatic Diseases *22. DYNAMIC CHANGES IN FRACTIONAL EXCRETION OF FILTERED SODIUM (FENa) AFTER RENAL Hong CD, Kapoor BS, First MR, and Pollak VE VII International Congress of Nephrology *23. INJECTION OF ALTERED HUMAN ALBUMIN (pI 9.6) IN THE RAT: INDUCTION OF INCREASED GLOMERULAR PERMEABILITY AND ACUTE RENAL FAILURE Pesce AJ, Miller WC, Clyne DH, First MR, Bramlage R, Purtell JN, and VII International Congress of Nephrology *24. VOLUME EXPANSION, OSMOTIC DIURESIS AND FUROSEMIDE DIURESIS ON RENAL ALBUMIN First MR, Patel VB, Sloan DE, Pesce Aj, and Pollak VE VII International Congress of Nephrology * 25. NON-SPECIFIC DEFENSE AGAINST INFECTION DURING THE EARLY POST-TRANSPLANT PERIOD Alexander JW, Stinnett JD, Ogle CK, Bright MW, and First MR Proceedings of New Frontiers in Transplantation, Rome, Italy, 1978 *26. THE CORRELATION OF KIDNEY TRANSPLANT SURVIVAL WITH LYMPHOCYTE MEDIATED National Kidney Foundation Clinical Dialysis and Transplant Forum, 1978 *27. EXPERIENCE WITH EXPANDED POLYTETRAFLEUROETHYLENE (PTFE) AS A SECONDARY PROCEDURE FOR ANGIO-ACCESS IN HEMODIALYSIS PATIENTS Munda R, First MR, Alexander JW, and Linnemann CC National Kidney Foundation Clinical Dialysis and Transplant Forum, 1979 28. PNEUMOCYSTIS CARINII PNEUMONIA (PCP) FOLLOWING RENAL TRANSPLANTATION First MR, Hamoui T, Munda R, Alexander JW, and Fidler JP National Kidney Foundation Clinical Dialysis and Transplant Forum, 1978 *29. MEASUREMENT OF URINE UREA NITROGEN (UUN) AND CREATININE (UCr) ON THE IL 919 BY KINETIC Suddendorf LR, Kaplan LA, First MR, and Stien FA American Association for Clinical Chemistry Meeting, Chicago, May, 1979 30. AN APPROACH TO SURVIVAL ANALYSIS IN PATIENTS WITH CHRONIC RENAL FAILURE (ESRD) Garcia G, First MR, Samuels S., Kant KS, Hong CD, Ooi BS, and Pollak VE Proceedings of the 12th Annual Meeting of the American Society of *31. HLA -BW4 AND BW6 MATCHING AND RENAL ALLOGRAFT SURVIVAL National Kidney Foundation Clinical Dialysis and Transplant Forum, *32. STEROID WITHDRAWAL FOLLOWING HLA -IDENTICAL RELATED DONOR TRANSPLANTATION First MR, Munda R, Fidler JP, and Alexander JW 8th International Congress of the Transplant Society, Boston, 1980 *33. PROSPECTIVE LYMPHOCYTE MEDIATED CYTOTOXICITY ON B-CELL TARGETS AND THE SELECTION OF HUMAN KIDNEY ALLOTRANSPLANT RECIPIENTS Nathan P, Plessinger RT, Alexander JW, and First MR American Physiological Society Annual Meeting, Toronto, 1980 *34 MICROBIAL CONTAMINATION OF TRANSPLANTED CADAVER KIDNEYS Majeski JA, Alexander JW, First MR, Munda R, Fidler JP, and Craycraft TK lst Annual Meeting of the Surgical Infection Society, Chicago, 1981 *35. URINARY RETENTION CAUSED BY NON-ANATOMICAL URETHRAL OBSTRUCTION FOLLOWING RENAL Sugarman SR, Munda R, Alexander JW, and First MR American Society of Transplant Surgeons, Chicago, 1981 *36. THE SPECIFIC MIXED LYMPHOCYTE CULTURE (MLC)-LYMPHOCYTE MEDIATED CYTOTOXICITY (LMC) TEST TO MATCH RELATED DONORS AND RECIPIENTS FOR KIDNEY ALLOTRANSPLANTS Nathan P, Plessinger RT, Alexander JW, and First MR Federation of the American Society for Experimental Biology, Atlanta, 1981 *37. PULMONARY INFECTIONS FOLLOWING RENAL TRANSPLANTATION First MR, Munda R, Alexander JW, Linnemann CC, Jr., Fidler JP, and Majeski VIIIth International Congress of Nephrology, Athens, Greece, 1981 *38. COMPLICATIONS OF POLYTETRAFHOROETHYLENE (PTFE) GRAFTS FOR European Society for Surgical Research, Pavia, Italy, 1982 *39 BENEFICIAL EFFECT OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT First MR, Linnemann CC, Munda R, and Alexander JW 9th International Congress of the Transplant Society *40. DNCB TESTING PREDICTS EFFECT OF SPLENECTOMY ON RENAL Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, and Morris, MJ 5th Tripartite Meeting of the Society of University Surgeons *41. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS, SENSITIZATION AND OUTCOME IN RENAL First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR American Assoc. of Blood Banks, 35th Annual Meeting Anaheim, California, 1982, In, Transfusion, 1982, p. 403 *42. SIMULTANEOUS KIDNEY AND PANCREAS PROCUREMENT: THE CINCINNATI EXPERIENCE Munda R, Suttman MP, First MR, and Alexander JW International Congress on Organ Procurement, Maastricht, Netherlands, 1983 43. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS ANALYSIS OF RESULTS BY PERIODS. Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, and 3rd Annual Meeting of the Surgical Infectious Society 44. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS Munda R, First MR, Alexander JW, Linnemann CC, Fidler JP, and American Society of Transplant Surgeons, Chicago, Illinois, 1983 *45. ACUTE RENAL FAILURE DELAYS FIRST REJECTION EPISODE FOLLOWING CADAVERIC RENAL TRANSPLANTATION Imler G, Alexander JW, First MR, and Munda R American Society of Transplant Surgeons, Chicago, Illinois, 1983 *46. BENEFICIAL EFFECT OF PNEUMOCCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT RECIPIENTS First MR, Linnemann CC, Munda R, and Alexander JW American Society of Transplant Physicians, Chicago, Illinois, 1983 47. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS, SENSITIZATION OUTCOME IN RENAL TRANSPLANTS First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR American Society of Transplant Physicians, Chicago, Illinois, 1983 *48. CLINICAL EXPERIENCE WITH SEGMENTAL PANCREATIC ALLOGRAFTS Munda R, First MR, Webb C, and Alexander JW International Symposium on Organ Transplantation in Diabetics, *49. PRE-TRANSPLANT DONOR SPECIFIC TRANSFUSIONS AND SENSITIZATION First MR, Balakrishnan K, Alexander JW, Munda R, and Whitacre LR V International Congress of Immunology, Japan, 1983 *50. PROTEINURIA FOLLOWING TRANSPLANTATION: CORRELATION First MR, Vaidya P, Maryniak RC, Weiss MA, Munda R, Fidler JP, American Society of Transplant Physicians, Chicago, Illinois, 1984 *51. MEMBRANOUS GLOMERULOPATHY FOLLOWING KIDNEY TRANSPLANTATION. ASSOCIATION WITH RENAL VEIN THROMBOSIS IN TWO OF SEVEN CASES First MR, Mendoza N, Maryniak RC, and Weiss MA American Society of Transplant Physicians, Chicagio, Illinois, 1984 *52. TRANSPLANT GLOMERULOPATHY - EVOLUTION OF MORPHOLOGICALLY DISTINCT CHANGES Maryniak RC, Weiskittel P, First MR, and Weiss MA Ninth International Congress of Nephrology, Los Angeles, California, 1984 *53. PULMONARY INFECTIONS IN RENAL TRANSPLANT RECIPIENTS 3rd International Symposium on Infections in the Immunocompromised *54. BENEFICIAL EFFECT OF PNEUMOCOCAL POLYSACCHARIDE VACCINE IN RENAL TRANSPLANT RECIPIENTS First MR, Linnemann CL, Munda R, and Alexander JW 10th International Congress of the Transplant Society, Minneapolis, *55. EXPERIENCE WITH PANCREATIC ALLOGRAFTS IN RENAL TRANSPLANT RECIPIENTS Munda R, Alexander JW, First MR, LeRoith D, Joffe SN, and Frohman LA 10th International Congress of the Transplant Society *56. DONOR SPECIFIC PRETRANSPLANT BLOOD TRANSFUSIONS - SENSITIZATION PATTERNS Balakrishnan K, Whitacre L, First MR, Alexander JW, and Munda R International Symposium on Relevant Immunological Factors in Clinical Kidney Transplantation, Heidelberg, June, 1985 57. PHARMACOKINETICS AND DRUG INTERACTIONS OF CYCLOSPORINE AND ERYTHROMYCIN Wadhwa N, Schroeder T, O'Flaherty E, Pesce A, and First MR *58. LOW DOSE TRIPLE IMMUNOSUPPRESSIVE THERAPY IN RENAL TRANSPLANTATION First MR, Alexander JW, Wadhwa NK, Penn I, Munda R, and Fidler JP 5th Annual Meeting of American Society of Transplant Physicians, *59. THE EFFECT OF ORAL METOCLOPRAMIDE ON THE ABSORPTION OF ORAL CYCLOSPORINE Wadhwa NK, Schroeder T, O'Flaherty, Pesce E, Myre S, and First MR 5th Annual Meeting of American Society of Transplant Physicians, *60. PANCREATIC ALLOGRAFT EXOCRINE URINARY TRACT DIVERSION; PATHOPHYSIOLOGY Munda R, Tom WW, First MR, and Alexander JW American Society of Transplant Surgeons, Chicago, May, 1986 *61. HLA ANTIGENS IN DIABETIC END STAGE RENAL DISEASE Balakrishnan K, Wadhwa N, First MR, Munda R, Whitacre L, and 6th International Congress of Immunology, Toronto, July, 1986 *62. CYCLOSPORINE COMPARISONS INVOLVING CHANGES IN MATRIXES AND METHODS Schroeder TJ, Pesce AJ, Wadhwa NK, and First MR 38th National Meeting of the American Association for Clinical *63. PHYSIOLOGIC CONSEQUENCES OF PANCREATIC ALLOGRAFT EXOCRINE DRAINAGE INTO THE URINARY TRACT Tom WW, Munda R, First MR, and Alexander JW 11th International Congress of the Transplantation Society *64. SYNCHRONOUS PANCREATIC AND RENAL ALLOGRAFTS WITH URINARY TRACT DRAINAGE OF THE PANCREAS Munda R, First MR, Weiss MA, and Alexander JW 11th International Congress of the Transplantation Society *65. THE EFFECT OF ORAL METOCLOPRAMIDE ON THE ABSORPTION OF CYCLOSPORINE Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, and First MR 11th International Congress of the Transplantation Society, *66. PRELIMINARY CYCLOSPORINE PHARMACOKINETIC COMPARISONS IN ADULT AND ADOLESCENT RENAL TRANSPLANTS AND ADULT CARDIAC TRANSPLANTS Schroeder T, Clardy C, Wadhwa N, McEnery P Pesce A, Melvin D, and *67. CURRENT EXPERIENCE WITH RENAL TRANSPLANTATION IN ELDERLY PATIENTS Shah B, First MR, Alexander JW, Penn I, Munda R, and Fidler J 16th Annual Scientific Meeting, National Kidney Foundation, Inc., *68. PANCREAS TRANSPLANTATION AT THE UNIVERSITY OF CINCINNATI Munda R, First MR, Weiss MA, and Alexander JW Second International Workshop in Clinical Pancreatic Transplantation, 69. A NEW METHOD FOR PHARMACOKINETIC MODELING OF CYCLOSPORINE Clardy C, Schroeder T, Wadhwa N, McEnery P, Pesce A, Melvin D, and 19th Annual Meeting of the American Society of Nephrology, *70. THE USE OF CYCLOSPORINE AND KETOCONAZOLE WITHOUT NEPHROTOXICITY IN TWO HEART TRANSPLANT RECIPIENTS Schroeder TJ, Melvin DB, Clardy CW, Myre SA, Reising JM, Wolf RK, 7th Annual Scientific Session, The International Society for Heart Transplantation, New Orleans, March, 1987 * 71. TRANSPLANTATION IN PATIENTS WITH HIGH PANEL REACTIVE Balakrishnan K, Whitacre L, Tressler T, First MR, Alexander JW, Munda R, American Society of Transplant Surgeons, Chicago, 1987 * 72. LOW DOSE CYCLOSPORINE IN RENAL TRANSPLANTATION; 3 YEARS Wadhwa NK, First MR, Alexander JW, Balakrishnan K, Munda R, Penn I, American Society of Transplant Physicians, Chicago, May, 1987 *73. CURRENT EXPERIENCE WITH RENAL TRANSPLANTATION IN PATIENTS 50 YEARS AND ABOVE Shah BV, First MR, Munda R, Penn I, Fidler JP, and Alexander JW American Society of Transplant Physicians, Chicago, May, 1987 *74. CLINICAL EFFICACY AND SIDE EFFECTS OF OTHOCLONE OKT3 IN RENAL PANCREATIC, HEPATIC AND CARDIAC TRANSPLANTATION Schroeder TJ, Weiskittel P, Bailey D, Melvin DB, Munda R, Clardy CW, Balisteri WF, Penn I, Fidler JP, Alexander JW, and First MR American Society of Transplant Physicians, Chicago, May, 1987 *75. THE CLINICAL VARIABILITY OF CYCLOSPORINE PHARMACOKINETICS IN ADULT AND PEDIATRIC RENAL, CARDIAC, HEPATIC, AND BONE MARROW TRANSPLANTS Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balisteri WF, Harris RE, and Melvin DB American Society of Transplant Physicians, Chicago, 1987 *76. INCIDENCE AND MORBIDITY OF CYTOMEGALOVIRUS DISEASE ASSOCIATED WITH A SERONEGATIVE RECIPIENT RECEIVING SEROPOSITIVE DONOR SPECIFIC TRANSFUSION AND LIVING RELATED DONOR TRANSPLANTATION: A MULTI-CENTER EVALUATION Weir MR, Henry ML, Blackmore M, Smith J, First MR, Irwin B, and Shen, S American Society of Transplant Physicians, Chicago, May, 1987 *77. CLINICAL VARIABILITY OF CYCLOSPORINE PHARMACOKINETICS Clardy CW, Schroeder TJ, Wadhwa NK, Pesce AJ, First MR, Myre SA, McEnery PT, Balisteri WF, Harris RE, and Melvin DB 39th Annual Meeting of the American Association for Clinical *78. CHANGES IN CYLCLOSPORINE METABOLISM WITH CO-ADMINISTRATION OF KETOCONAZOLE Schroeder TJ, Melvin DB, Clardy CW, Wadhwa NK, Myre SA, Reising JM, Wolf RK, Collins JA, Pesce AJ, and First MR 39th Annual Meeting of the American Association for Clinical Chemistry 79. HLA ANTIGENS AND DONOR SPECIFIC BLOOD TRANSFUSION IN DIABETIC RENAL ALLOGRAFT RECIPIENTS Wadhwa NK, Balakrishnan K, First MR, Whitecre L, and Alexander JW 10th International Congress of Nephrology, London, July, 1987 80. LOW DOSE CYCLOSPORINE IN CACAVERIC RENAL TRANSPLANTATION: 3 YEARS EXPERIENCE Wadhwa NK, First MR, Alexander JW, Balakrishnan K, Munda R, Penn I, Second International Congress on Cyclosporine *81. USE OF CYCLOSPORINE BY CONSTANT-RATE INTRAVENOUS INFUSION IMMEDIATELY FOLLOWING HEART TRANSPLANTATION Myre S, Schroeder T, Clardy C, First MR, Pesce A, Wadhwa N, and Melvin D Second International Congress on Cyclosporine *82. CYCLOSPORINE PHARMACOKINETICS IN PANCREAS TRANSPLANT RECIPIENTS Munda R, Schroeder TJ, Pedersen S, Clardy CW, Washwa NK, Myre SA, Second International Congress on Cyclosporine *83. EVALUATION OF ABBOTT TDX FLUROESCENCE POLARIZATION IMMUNOASSAY AND SANDOZ RADIOIMMUNOASSAY METHODS FOR THE ASSAY OF SERUM CYCLOSPORINE Schroeder TJ, Pesce AJ, Hasson FM, Wermeling JR, and First MR Second International Congress on Cyclosporine *84. LYMPHOCYTE SUBSET ANALYSIS IN TRANSPLANT RECIPIENTS TREATED WITH EITHER RABBIT ANTITHYMOCYTE SERUM OF ORTHOCLONE OKT3 Schroeder TJ, Hurtubise PE, Marmer DJ, Melvin DB, Collins JA, Alexander 2nd Annual Meeting on Clinical Application of Cytometry *85. USE OF ORTHOCLONE OKT3 IN HEPATIC ALLOGRAFT TRANSPLANT RECIPIENTS Schroeder TJ, Balistreri WF, Pedersen SH, Ryckman FC, Suchy FJ, Noseworthy J, Blitzer B, Foote M, Penn I, Alexander JW, and First MR Am. Assoc. for the Study of Liver Disease, Chicago, October, 1987 86. SURVIVAL PATTERNS IN LUPUS NEPHRITIS WITH END-STAGE RENAL DISEASE Wadhwa NK, Kant KS, Clyne DH, First MR, and Pollak VE 20th Annual Meeting of American Society of Nephrology 87. EFFECT OF CYCLOSPORINE ON FRACTIONAL EXCRETION OF SODIUM IN RENAL TRANSPLANT 20th Annual Meeting of American Society of Nephrology *88. OUTCOME OF KIDNEY TRANSPLANTS ACROSS B CELL POSITIVE CROSSMATCHES Balakrishnan K, Munda R, First MR, and Alexander JW Biology of Transfusion Induced Immunosuppression *89. CYCLOSPORINE PHARMACOKINETICS IN PANCREAS TRANSPLANT RECIPIENTS First International Congress on Pancreatic and Islet Transplantation *90. LONG TERM EFFECTS OF SUCCESSFUL PANCREAS ALLOGRAFT TRANSPLANTATION Munda R, First MR, Pedersen S, Kranias G, and Alexander JW First International Congress on Pancreatic and Islet Transplantation *91. THE EFFICACY, TOXICITY AND PREDICTABILITY OF CONSTANT-RATE INTRAVENOUS CYCLOSPORINE INFUSION IMMEDIATELY FOLLOWING CARDIAC TRANSPLANTATION 8th Annual Meeting of the International Society for Heart Transplantation, *92. USE OF ORTHOCLONE OKT3 IN PEDIATRIC LIVER ALLOGRAFT TRANSPLANT RECIPIENTS Schroeder TJ, Balistreri WF, Ryckman FC, Suchy FJ, Pedersen SH, Foote M, The American Pediatric Society/The Society for Pediatric Research *93. CYCLOSPORINE-ASSOCIATED GLOMERULAR AND ARTERIOLAR THROMBOSIS FOLLOWING RENAL First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, American Society of Transplant Physicians, Chicago, June, 1988 *94. THE TDx FLUROESCENT POLARIZATION IMMUNOASSAY (PPIA) PROVIDES RAPID CYCLOSPORINE Schroeder T, Brunson M, Pesce A, Hindenlang L, Mauser P, Ruckrigl D, American Society of Transplant Physicians, Chicago, June, 1988 *95. PREDNISONE WITHDRAWAL IN HLA -IDENTICAL LIVING RELATED DONOR TRANSPLANT RECIPIENTS Hariharan S, First MR, Munda R, Penn I, Schroeder TJ, Fidler JP, American Society of Transplant Physicians, Chicago, June, 1988 *96. SUCCESSFUL RETREATMENT OF REJECTION WITH ORTHOCLONE OKT3 First MR, Schroeder TJ, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler Jp, Ryckman FC, and Brunson ME American Society of Transplant Surgeons, Chicago, June, 1988 *97. EVALUATION OF THE TDXR FLUORESCENT POLARIZATION IMMUNOASSAY (PPIA) FOR THE Schroeder TJ, Pesce A, Mauser P, Weibel M, Hindenlang L, and First MR American Association of Clinical Chemists, New Orleans, July, 1988 *98. EVALUATION OF TDXR FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA) FOR THE MONITORING Schroeder TJ, Pesce AJ, Hindenlang L, Ruckrigl D, Mauser P, Wadih G, American Association of Clinical Chemists, New Orleans, July, 1988 *99. TDx FLUORESCENT POLARIZATION IMMUNOASSAY (FPIA) PROVIDES RAPID CYCLOSPORINE LEVELS Pesce AJ, Schroeder T, Brunson M, Hindenlach L, Mauser P, Ruckrigl D, 12th International Congress of the Transplantation Society, *100. CYCLOSPORINE-ASSOCIATED GLOMERULAR AND ARTERIOLAR THROMBOSIS FOLLOWING RENAL Smith R, First MR, Weiss M, Kant KS, Munda R, Stephens G, Penn I, 12th International Congress of the Transplantation Society, *101. SUCCESSFUL RETREATMENT OF REJECTION WITH ORTHOCLONE OKT3 First MR, Schroeder T, Penn I, Munda R, Balistreri W, Alexander JW, 12th International Congress of the Transplantation Society, *102. PREDNISONE WITHDRAWAL IN HLA -IDENTICAL LIVING RELATED DONOR TRANSPLANT RECIPIENTS Hariharan S, First MR, Munda R, Penn I, Fidler J, and Weiskittel P 12th International Congress of the Transplantation Society, *103. COMPARISON OF THE SAFETY AND EFFICACY OF ORAL VS CONSTANT-RATE INTRAVENOUS INFUSION CYCLOSPORINE IMMEDIATELY FOLLOWING ORTHOTOPIC HEART TRANSPLANTATION Myre S, Melvin D, Pesce A. Schroeder T, Collins J, Stephens G, Kahn A, 12th International Congress of the Transplantation Society, *104. LONG TERM EFFECTS OF SUCCESSFUL PANCREAS ALLOGRAFT TRANSPLANTATION Munda R, First MR, Pedersen S, Kranias G, and Alexander JW 12th International Congress of the Transplantation Society, *105. INFECTION IN OKT3 TREATED PATIENTS HAVING MULTIPLE REJECTION EPISODES Munda R, Hutchins M, First MR, Carey M, Schroeder T, and Alexander JW 12th International Congress of the Transplantation Society, *106. OUTCOME OF KIDNEY TRANSPLANTS ACROSS B CELL POSITIVE CROSSMATCHES Balakrishnan K, Munda R, First MR, and Alexander JW 12th International Congress of the Transplantation Society, *107. ASSESSING DONOR AND RECIPIENT LIVER FUNCTION; A RAPID AND REPRODUCIBLE TECHNIQUE Schroeder T, Gremse D, Mansour M, Balistreri W, Theurling A, Brunson M, Ryckman F, Suchy F, Penn I, 12th International Congress of the Transplantation Society, *108. PRETRANSPLANT INTERLEUKIN-2 RECEPTOR LEVELS IN LIVING RELATED DONOR KIDNEY RECIPIENTS RECEIVING DONOR SPECIFIC BLOOD TRANSFUSIONS Harden EA, Schroeder TJ, Munda R, Brunson ME, Hurtubise PE, Pesce AJ, Balakrishnan K, Alexander American Federation for Clinical Research, Chicago, Illinois, Nov., 1988 *109. IMMUNOLOGIC MONITORING DURING RETREATMENT WITH OKT3 First MR, Schroeder TJ, Hurtubise PE, and Monsour ME. American Society of Nephrology, San Antonio, Texas, Dec., 1988 *110. PRE-TRANSPLANT INTERLEUKIN-2 RECEPTOR LEVELS IN LIVING RELATED DONOR KIDNEY RECIPIENTS RECEIVING DONOR SPECIFIC BLOOD TRANSFUSIONS Harden EA, Schroeder TJ, Munda R, Brunson ME, Hurtubise PE, Pesce AJ, Balakrishnan K, Alexander American Society of Nephrology, San Antonio, Texas, Dec., 1988 *111. PROPHYLACTIC USE OF OKT3 IN IMMUNOLOGICAL HIGH RISK CADAVER TRANSPLANT RECIPIENTS First MR, Schroeder TJ, Mansour ME, Alexander JW, and Penn I American Society of Transplant Physicians, Chicago, Illinois, May, 1989 *112. ANTIMURINE ANTIBODY FORMATION FOLLOWING OKT3 THERAPY Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, and Melvin American Society of Transplant Physicians, Chicago, Illinois, May, 1989 *113. KETOCONAZOLE PREDICTABLY REDUCES CYCLOSPORINE DOSING REQUIREMENTS WITHOUT Myre SA, Schroeder TJ, Grund VR, Wandstrat TL, Abbott LJ, Pesce AJ, *114. THE USE OF MONOCLONAL ANTIBODY OKT3 IN SOLID ORGAN TRANSPLANTATION American Association of Colleges of Pharmacy and Association of Faculties of Pharmacy of Canada, *115. CYCLOSPORINE KINETICS WITH CONCOMITANT KETOCONAZOLE THERAPY Schroeder TJ, Weiskittel P, Pesce AJ, Myre, SA, Alexander JW, and First MR American Association of Clinical Chemists, Atlanta, Georgia, July, 1989 *116. POST-TRANSPLANT ANTI-GBM NEPHRITIS (GN) IN RELATED ALPORT MALES: TARGET ANTIGEN Kashtan R, Butkowski R, Kleppel M, First MR, Weislander, Jr., and American Society of Nephrology, 22nd annual meeting *117. THE ABBOTT TDX FLORESCENT POLARIZATION IMMUNOASSAY (FPIA) PROVIDES A RAPID AND ACCURATE MEASUREMENT OF CYCLOSPORINE AND METABOLITIES Expert Workshop: Optimal use of cyclosporine and therapeutic drug *118. CYCLOSPORINE PHARMACOKINETICS WITH CONCOMITANT KETOCONAZOLE THERAPY (CP-525) Schroeder TJ, Weiskittel P, Pesce AJ, Myre A, Alexander JW, and First MR Clinical and Diagnostic Immunology Division , American Association for Clinical Chemistry, Newsletter, 4:13-14, 1990 *119. CLINICAL CORRELATIONS OF CYCLOSPORINE HPLC AND FPIA LEVELS IN RENAL TRANSPLANT Sridhar N, Schroeder TJ, Pesce AJ, and First MR Expert Workshop: Optimal use of cyclosporine and therapeutic drug monitoring, Hawk's Cay, Florida, January, 1990 *120. CLINICAL CORRELATIONS OF CYCLOSPORINE SPECIFIC AND NON-SPECIFIC ASSAYS IN STABLE RENAL TRANSPLANTS, ACUTE REJECTION, AND NEPHROTOXICITY Schroeder TJ, Sridhar N, Pesce AJ, Alexander JW, and First MR American Society of Transplant Physicians, 9th annual meeting *121. CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL TRANSPLANT First MR, Schroeder TJ, Weiskittel P, Stephens GW, Myre SA, Alexander JW, American Society of Transplant Physicians, 9th annual meeting *122. THE EFFICACY OF OKT3 IN ACTIVE VASCULAR REJECTION Schroeder TJ, Weiss MA, Smith RD, Stephens GW, and First MR American Society of Transplant Physicians, 9th annual meeting *123. USE OF KIDNEYS FOR TRANSPLANTATION FROM HIGH RISK DONORS Alexander JW, Sc D, First MR, Craycraft BS, Munda R, Penn I, Fidler JP, American Society of Transplant Physicians, 9th annual meeting *124. CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL TRANSPLANT First MR, Schroeder TJ, Weiskittel P, Stephens GW, Myre SA, and Pesce AJ International Congress of Nephrology, Tokyo, Japan, July, 1990 *125. MEASUREMENT OF ADENOSINE DEAMINASE BINDING PROTEIN (ABP) AS A MONITOR OF RENAL Schroeder TJ, Pesce AJ, Nauman PM, and First MR International Congress of Nephrology, Tokyo, Japan, July, 1990 *126. BETA-2-MICROGLOBULIN LEVELS IN PATIENTS WITH RENAL DISEASE EVALUATED BY THE ABBOTT Pesce AJ, Schroeder TJ, Chavinson D, Horowitz ME, and First MR International Congress of Nephrology, Tokyo, Japan, July, 1990 *127. THE EFFICACY OF OKT3 IN ACUTE VASCULAR REJECTION Schroeder TJ, Weiss MA, Smity RD, Stephens GW, and First MR 13th International Congress of the Transplantation Society *128. EFFICACY OF INDUCTION THERAPY IN CADAVERIC RENAL TRANSPLANTATION COMPARING RATS Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, Sc D, and First MR 13th International Congress of the Transplantation Society *129. CYCLOSPORINE (CsA) PRETRANSPLANTATION REDUCES REJECTION EPISODES AND IMPROVES ALLOGRAFT FUNCTION IN LIVING RELATED 1-HAPLOTYPE MISMATCHED RENAL (HMLR) TRANSPLANT PATIENTS Tchervenkov J, Brunson M, Alexander W, Schroeder T, First MR, Munda R, American Society of Neprhology, 23rd annual meeting *130. MEASUREMENT OF ADENOSINE DEAMINASE BINDING PROTEIN AS A MONITOR OF RENAL FUNCTION Schroeder T, Nauman P, Pesce A, and First MR American Society of Nephrology, 23rd annual meeting *131. RAPID SOLUBLE INTERLEUKIN-2 RECEPTOR ANALYSIS IN RENAL TRANSPLANT RECIPIENTS SERA BY Muth KL, Schroeder TJ, Martin LA, Hindenlang L, Traylor D, Pesce AJ, American Society of Nephrology, 23rd annual meeting *132. MALIGNANCIES FOLLOWING RENAL TRANSPLANTATION: INCIDENCE AND CLINICAL COURSE The Ohio State Radiological Society, 51st annual meeting *133. RETROSPECTIVE STUDY OF THE ECONOMICS OF RENAL TRANSPLANT WITH OKT*3 VS. MALG OR American Society of Transplant Physicians, 10th annual meeting *134. THE ECONOMICS OF TRANSPLANTATION: ATTITUDES AND KNOWLEDGE OF THE RENAL American Society of Transplant Physicians, 10th annual meeting *135. CYCLOSPORINE (CYA) DOSING AND BLOOD LEVELS IN RENAL TRANSPLANT RECIPIENTS RECEIVING Sridhar N, Schroeder SJ, Hariharan S, Pesce AJ, and First MR American Society of Transplant Physicians, 10th annual meeting *136. THE USE OF INDOMETHACIN TO DECREA SE THE EARLY ADVERSE EFFECTS OF OKT3 First MR, Schroeder TJ, Hariharan S, Alexander JW, and Weiskittel P American Society of Transplant Physicians, 10th annual meeting *137. A MULTI-CENTER STUDY TO EVALUATE A NOVEL ASSAY FOR QUANTITATION OF SOLUBLE INTERLEUKIN-2 RECEPTOR (SlL-2R) IN RENAL TRANSPLANT RECIPIENTS Schroeder T, Helling T, McKenna R, Rush D, Jeffrey J, Brewer B, Martin L, American Society of Transplant Physicians, 10th annual meeting *138. RENAL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Hariharan S, Schroeder TJ, Carey MA, and First MR American Society of Transplant Physicians, 10th annual meeting *139. IMMUNOLOGIC HYPORESPONSIVENESS IS INDUCED BY DONOR SPECIFIC TRANSFUSIONS (DST) AND CYCLOSPORINE (CsA) IN HUMAN CADAVERIC TRANSPLANTS Alexander JW, Babcock GF, Madden RL, Munda R, Penn I, Fidler JP, First MR, Stephens G, Schroeder T, Cardi M, Manzler A, Cohen L, American Society of Transplant Surgeons, Chicago, Illinois, July, 1991 *140. EVALUATION OF THE NEW CYCLOSPORINE MONOCLONAL ANTIBODY FLUORESCENT POLARIZATION IMMUNOASSAY IN CARDIAC AND RENAL TRANSPLANTS Schroeder T, Vine W, Ruckrigl D, Pesce A, Bhat G, and First MR American Association of Clinical Chemists, Washington, D.C., July, 1991 *141. FLOCYTOMETRIC CROSSMATCHING IN RENAL TRANSPLANTATION: EXPERIENCE WITH QUADRUPLE IMMUNOSUPPRESSION Sridhar N, Munda R, Balakrishnan K, and First MR American Society for Histocompatibility and Immunogenics, 17th annual meeting, Washington, D.C., October, 1991 *142. FLOWCYTOMETRIC EVALUATION OF CYTOTOXIC PERIPHERAL BLOOD LYMPHOCYTES IN ACUTE RENAL GRAFT REJECTION Sridhar N, Blanton M. Whitacre L, Balakrishnan K, and First MR American Society of Nephrology, 24th annual meeting *143. EXPERIENCE WITH PREDNISONE REDUCTION AND WITHDRAWAL IN LIVE AND CADAVER RENAL American Society of Nephrology, 24th annual meeting *144. RAPID DETECTION OF ANTI-OKT3 ANTIBODIES Schroeder TJ, First MR, Hariharan S, Pouletty C, and Pouletty P American Society of Nephrology, 24th annual meeting *145. EFFICACY OF A SINGLE DONOR SPECIFIC TRANSFUSION AND CYCLOSPORINE A ADMINISTERED ONE DAY PRIOR TO ONE-HAPLOTYPE MISMATCHED LIVING RELATED DONOR KIDNEY TRANSPLANTATION Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ Southern Surgical Association, 130th annual meeting *146. INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLPD) IN OKT3 - TREATED Anderson PJ, Schroeder TJ, Hariharan S, First MR American Society of Transplant Physicians, 11th annual meeting *147. CYCLOSPORINE A (CYA) DOSING AND BLOOD LEVELS IN RENAL TRANSPLANT RECIPIENTS RECEIVING DILTIAZEM (SLOW RELEASE) 180 MG AND 240 MG DAILY Hariharan S, Schroeder TJ, Michael AT, First MR American Society of Transplant Physicians, 11th annual meeting *148. OKT3 MONOCLONAL ANTIBODY THERAPY AS A FIRST LINE AGENT IN ACUTE RENAL ALLOGRAFT Schroeder TJ, First MR, Michael AT, Hariharan S American Society of Transplant Physicians, 11th annual meeting

Source: http://www.ipittr.org/docs/cv_first.pdf